


**CUMULATIVE
SUPPLEMENT 07
July 2009**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Cumulative Supplement 7

July 2009

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	vii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**CUMULATIVE SUPPLEMENT 7
July 2009**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 29th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABLE LABORATORIES INC (ABLE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
AXIOM PHARMACEUTICAL CORP (AXIOM PHARM)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)
HALSEY DRUG CO INC (HALSEY)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS (IVAX PAHRMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)

NORTON WATERFORD LTD (NORTON WATERFORD)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
TORPHARM INC (TORPHARM)	APOTEX INC (APOTEX)
ZENITH GOLDLINE (ZENTH GOLDLINE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and

those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2008	MAR 2009	JUN 2009	SEPT 2009
DRUG PRODUCTS LISTED	12751	12910	13027	
SINGLE SOURCE	2433 (19.1%)	2449 (19.0%)	2451 (18.8%)	
MULTISOURCE	10229 (80.2%)	10372 (80.3%)	10487 (80.5%)	
THERAPEUTICALLY EQUIVALENT	10072 (79.0%)	10216 (79.1%)	10333 (79.3%)	
NOT THERAPEUTICALLY EQUIVALENT	157 (1.2%)	156 (1.2%)	154 (1.2%)	
EXCEPTIONS ¹	89 (0.7%)	89 (0.7%)	89 (0.7%)	
NEW MOLECULAR ENTITIES APPROVED	15	5	6	
NUMBER OF APPLICANTS	719	724	732	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PREScription DRUG PRODUCT LIST - 28TH EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

1-1

ACARBOSE

TABLET; ORAL
ACARBOSE

AB	IMPAX LABS	25MG	N78441 001 May 14, 2009 May NEWA
AB		50MG	N78441 002 May 14, 2009 May NEWA
AB		100MG	N78441 003 May 14, 2009 May NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AB	MUTUAL PHARM	325MG;50MG;40MG	N40601 001 Jul 29, 2005 Jul DISC
>A>		@	325MG;50MG;40MG	N40601 001 Jul 29, 2005 Jul DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

@	SANDOZ	300MG;30MG	N81250 001 Jul 16, 1992 Mar DISC
@		300MG;60MG	N81249 001 Jul 16, 1992 Mar DISC

TYLENOL W/ CODEINE NO. 4

AA	ORTHO MCNEIL JANSSEN	300MG;60MG	N85055 004 Mar CMFD
----	----------------------	------------	---------------------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	MALLINCKRODT	500MG;5MG	N89006 001 Aug 09, 1985 Feb CTNA
---	--------------	-----------	----------------------------------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
PERCOSET

AA	+ ENDO PHARMS	325MG;2.5MG	N40330 001 Jun 25, 1999 May CTEC
----	---------------	-------------	----------------------------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@	SANDOZ	650MG;65MG	N89959 001 Jul 18, 1989 Mar DISC
---	--------	------------	----------------------------------

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@	SANDOZ	650MG;100MG	N70443 001 Jan 23, 1986 Mar DISC
---	--------	-------------	----------------------------------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	MYLAN	325MG;37.5MG	N77858 001 Sep 26, 2008 Apr CAHN
----	-------	--------------	----------------------------------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

@	HOSPIRA	EQ 500MG BASE/VIAL	N40108 001 Oct 30, 1995 Apr DISC
---	---------	--------------------	----------------------------------

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC VOSOL	>D>	@ HI TECH PHARMA	2%	N12179 001	Jul	CMFD
	>A>	AT	2%	N12179 001	Jul	CMFD

ACYCLOVIR

CAPSULE; ORAL ACYCLOVIR @ BELCHER PHARMS	200MG	N74889 001	Oct 31, 1997	Jun	CAHN
TABLET; ORAL ACYCLOVIR @ BELCHER PHARMS	400MG	N74891 001	Oct 31, 1997	Jun	CAHN
	800MG	N74891 002	Oct 31, 1997	Jun	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION ACYCLOVIR SODIUM @ HOSPIRA	EQ 500MG BASE/VIAL	N74758 001	Apr 22, 1997	Apr	DISC
	EQ 1GM BASE/VIAL	N74758 002	Apr 22, 1997	Apr	DISC

>A> ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL ACYCLOVIR AND HYDROCORTISONE + MEDIVIR	5%;1%	N22436 001	Jul 31, 2009	Jul	NEWA
---	-------	------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION ADENOSINE					
AP LUITPOLD	3MG/ML	N90010 001	Apr 28, 2009	Apr	NEWA
AP STRIDES ARCOLAB LTD	3MG/ML	N78686 001	May 13, 2009	May	NEWA
AP WOCKHARDT	3MG/ML	N90220 001	Jul 20, 2009	Jun	NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION ALBUTEROL @ ARMSTRONG PHARMS	0.09MG/INH	N72273 001	Aug 14, 1996	Jan	DISC
---	------------	------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION ALBUTEROL SULFATE @ BAUSCH AND LOMB	EQ 0.083% BASE	N75358 001	Mar 29, 2000	Apr	DISC
AN HOLOPACK INTL	EQ 0.083% BASE	N77839 001	Dec 16, 2008	Jan	CAHN
AN TEVA PARENTERAL	EQ 0.083% BASE	N75343 001	Nov 09, 1999	Apr	CAHN
TABLET; ORAL ALBUTEROL SULFATE @ SANDOZ	EQ 2MG BASE	N72151 001	Dec 05, 1989	Mar	DISC
	EQ 4MG BASE	N72152 001	Dec 05, 1989	Mar	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE AN TEVA PARENTERAL	EQ 0.083% BASE;0.017%	N76724 001	Dec 31, 2007	Apr	CAHN
---	-----------------------	------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ALCLOMETASONE DIPROPIONATE

AB	GLENMARK GENERICS	0.05%	N79061 001 Jun 23, 2009 Jun NEWA
OINTMENT; TOPICAL ALCLOMETASONE DIPROPIONATE			
>A>	AB	GLENMARK GENERICS	0.05% N79227 001 Jul 30, 2009 Jul NEWA

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

AB	SANDOZ	EQ 5MG BASE	N75871 001 Apr 22, 2009 Apr NEWA
AB		EQ 10MG BASE	N75871 002 Apr 22, 2009 Apr NEWA
AB		EQ 35MG BASE	N75871 004 Apr 22, 2009 Apr NEWA
AB		EQ 40MG BASE	N75871 003 Apr 22, 2009 Apr NEWA
AB		EQ 70MG BASE	N75871 005 Apr 22, 2009 Apr NEWA

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

@	SANDOZ	100MG	N70268 001 Dec 31, 1985 Mar DISC
@		300MG	N70269 001 Dec 31, 1985 Mar DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE

AB	+ PAR PHARM	5MG	N70346 001 Jan 22, 1986 Jan CTEC
AB	SIGMAPHARM LABS LLC	5MG	N79133 001 Jan 30, 2009 Jan NEWA
MIDAMOR			
AB	PADDOCK LABS	5MG	N18200 001 May CMFD

AMILORIDE HYDROCHLORIDE; HYDROCHLORTIAZIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLORTIAZIDE

@	SANDOZ	EQ 5MG ANHYDROUS;50MG	N73357 001 Nov 27, 1991 Mar DISC
---	--------	-----------------------	----------------------------------

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID

@	HOSPIRA	250MG/ML	N70888 001 Jun 16, 1988 Apr DISC
TABLET; ORAL AMICAR			
XANODYNE PHARM	1GM		N15197 002 Jun 24, 2004 Jan NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	+ HOSPIRA	25MG/ML	N87242 001 Oct 26, 1983 Jun CRLD
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%			
@	HOSPIRA	100MG/100ML	N88147 002 May 03, 1983 Apr DISC
@		200MG/100ML	N88147 003 May 03, 1983 Apr DISC
>D>	SUPPOSITORY; RECTAL		
>D>	TRUPHYLLINE		
>D>	G AND W LABS	250MG	N85498 001 Mar 23, 1983 Jul DISC
>A>	@	250MG	N85498 001 Mar 23, 1983 Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ INTL MEDICATION SYS 50MG/ML

N21594 001 Feb 04, 2004 Jun DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MYLAN 200MG

N75188 001 Feb 24, 1999 Apr CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ALKEM	EQ 2.5MG BASE
AB		EQ 5MG BASE
AB		EQ 10MG BASE
AB	GLENMARK GENERICS	EQ 2.5MG BASE
AB		EQ 5MG BASE
AB		EQ 10MG BASE
AB	ORCHID HLTHCARE	EQ 2.5MG BASE
AB		EQ 5MG BASE
AB		EQ 10MG BASE
AB	SYNTTHON PHARMS	EQ 2.5MG BASE
AB		EQ 5MG BASE
AB		EQ 10MG BASE

N78925 001	May 04, 2009	Apr	NEWA
N78925 002	May 04, 2009	Apr	NEWA
N78925 003	May 04, 2009	Apr	NEWA
N78552 001	Apr 08, 2009	Mar	NEWA
N78552 002	Apr 08, 2009	Mar	NEWA
N78552 003	Apr 08, 2009	Mar	NEWA
N78453 001	Jul 02, 2009	Jun	NEWA
N78453 002	Jul 02, 2009	Jun	NEWA
N78453 003	Jul 02, 2009	Jun	NEWA
N77080 001	Jun 27, 2007	Jan	CAHN
N77080 002	Jun 27, 2007	Jan	CAHN
N77080 003	Jun 27, 2007	Jan	CAHN

AMLODIPINE; HYDROCHLORTIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

NOVARTIS

5MG;12.5MG;160MG

N22314 001 Apr 30, 2009 Apr NEWA

5MG;25MG;160MG

N22314 002 Apr 30, 2009 Apr NEWA

10MG;12.5MG;160MG

N22314 003 Apr 30, 2009 Apr NEWA

+

10MG;25MG;320MG

N22314 005 Apr 30, 2009 Apr NEWA

10MG;25MG;160MG

N22314 004 Apr 30, 2009 Apr NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	APOTEX	250MG;EQ 125MG BASE
AB		500MG;EQ 125MG BASE

N65333 001	Feb 24, 2009	Feb	NEWA
N65333 002	Feb 24, 2009	Feb	NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE
	IOPIDINE	
AT	+ ALCON	EQ 0.5% BASE

N77764 001	Mar 12, 2009	Feb	NEWA
N20258 001	Jul 30, 1993	Feb	CFTG

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

100MG

N21875 002 Mar 26, 2009 Mar CMFD

200MG

N21875 005 Mar 26, 2009 Mar NEWA

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL
 COARTEM
 NOVARTIS 20MG;120MG N22268 001 Apr 07, 2009 Apr NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
 BUTALBITAL, ASPIRIN AND CAFFEINE
 @ SANDOZ 325MG;50MG;40MG N86398 002 Apr 06, 1984 Mar DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
 ORPHENGESIC
 @ SOLCO HLTHCARE 385MG;30MG;25MG N75141 001 May 29, 1998 Jan CAHN
 ORPHENGESIC FORTE
 @ SOLCO HLTHCARE 770MG;60MG;50MG N75141 002 May 29, 1998 Jan CAHN

ATENOLOL

TABLET; ORAL
 ATENOLOL
 AB IPCA LABS LTD 25MG N77877 001 Dec 27, 2006 Jun CAHN
 AB 50MG N77877 002 Dec 27, 2006 Jun CAHN
 AB 100MG N77877 003 Dec 27, 2006 Jun CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
 ATRACURIUM BESYLATE
 @ HOSPIRA 10MG/ML N74740 001 Mar 28, 1997 Jan DISC
 ATRACURIUM BESYLATE PRESERVATIVE FREE
 @ HOSPIRA 10MG/ML N74741 001 Mar 28, 1997 Jan DISC

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
 MOTOFEN
 + VALEANT 0.025MG;1MG N17744 002 Jun CMFD

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
 ENLON-PLUS
 >D> @ BIONICHE PHARMA 0.14MG/ML;10MG/ML N19677 001 Nov 06, 1991 Jul CMFD
 >A> + 0.14MG/ML;10MG/ML N19677 001 Nov 06, 1991 Jul CMFD

AZACITIDINE

INJECTABLE; IV-SC
 VIDAZA
 + CELGENE 100MG/VIAL N50794 001 May 19, 2004 Mar CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 >A> AZELASTINE HYDROCHLORIDE
 >A> AT APOTEX INC 0.05% N78621 001 Aug 03, 2009 Jul NEWA
 OPTIVAR
 >D> + MEDA PHARMS 0.05% N21127 001 May 22, 2000 Jul CFTG
 >A> AT + 0.05% N21127 001 May 22, 2000 Jul CFTG

SPRAY, METERED; NASAL
 AZELASTINE HYDROCHLORIDE
 @ APOTEX INC EQ 0.125MG BASE/SPRAY

N77954 001 Apr 30, 2009 Apr DISC

AZITHROMYCIN

INJECTABLE; INJECTION
 AZITHROMYCIN

AP	HOSPIRA	EQ 500MG BASE/VIAL	N65500 001 Jun 26, 2009 Jun NEWA
AP		EQ 500MG BASE/VIAL	N65511 001 Jun 26, 2009 Jun NEWA
AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	N65506 001 Mar 24, 2009 Mar NEWA

BACLOFEN

TABLET; ORAL
 BACLOFEN

AB	MYLAN	10MG	N77181 001 Jul 29, 2005 Apr CAHN
AB		20MG	N77121 002 Jul 29, 2005 Apr CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)
 TREANDA
 + CEPHALON 25MG/VIAL

N22249 002 May 01, 2009 May NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
 BENZACLIN

>D>	BT	+ SANOFI AVENTIS US	5%;EQ 1% BASE	N50756 001 Dec 21, 2000 Jul CFTG
>A>	AB	+	5%;EQ 1% BASE	N50756 001 Dec 21, 2000 Jul CFTG
>A>		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE		
>A>	AB	DOW PHARM SCIENCES	5%;EQ 1% BASE	N65443 001 Aug 11, 2009 Jul NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

>A>		BENZTROPINE MESYLATE		
>A>	AP	NEXUS PHARMS	1MG/ML	N90233 001 Jul 28, 2009 Jul NEWA
		COGENTIN		
>D>	+ LUNDBECK INC	1MG/ML		N12015 001 Jul CFTG
>A>	AP	+	1MG/ML	N12015 001 Jul CFTG
		+	1MG/ML	N12015 001 Apr CAHN

BENZYL ALCOHOL

LOTION; TOPICAL
 BENZYL ALCOHOL
 + SCIELE PHARMA INC 5%
 ULESFIA
 + SCIELE PHARMA INC 5%

N22129 001 Apr 09, 2009 Apr NEWA
 N22129 001 Apr 09, 2009 May CTNA

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
 BESIVANCE
 + BAUSCH AND LOMB EQ 0.6% BASE

N22308 001 May 28, 2009 May NEWA

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

>A>		BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE		
>A>	AB	PHARMAFORCE	3MG/ML;EQ 3MG BASE/ML	N90747 001 Jul 31, 2009 Jul NEWA

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

>D>	+ SCHERING	3MG/ML; EQ 3MG BASE/ML	N14602 001	Jul	CFTG
>A> AB	+	3MG/ML; EQ 3MG BASE/ML	N14602 001	Jul	CFTG

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM	0.064%; 0.005%	N21852 001	Jan 09, 2006	Mar	CAHN
-------------	----------------	------------	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ CONNECTICS	EQ 0.12% BASE	N20934 001	Feb 28, 1999	May	CAHN
--------------	---------------	------------	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	SUN PHARM IND'S INC	5MG	N40897 001	Apr 22, 2009	Apr	NEWA
AA		10MG	N40897 002	Apr 22, 2009	Apr	NEWA
AA		25MG	N40897 003	Apr 22, 2009	Apr	NEWA
AA		50MG	N40897 004	Apr 22, 2009	Apr	NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE INC	50MG	N78917 001	Jul 06, 2009	Jun	NEWA
AB	KUDCO IRELAND	50MG	N77995 001	Jul 06, 2009	Jun	NEWA
AB	MYLAN	50MG	N79185 001	Jul 06, 2009	Jun	NEWA
AB	SANDOZ	50MG	N78575 001	Jul 06, 2009	Jun	NEWA
AB	SUN PHARMA GLOBAL	50MG	N79110 001	Jul 06, 2009	Jun	NEWA
AB	SYNTON PHARMS	50MG	N77973 001	Jul 06, 2009	Jun	NEWA
AB	TEVA	50MG	N76932 001	Jul 06, 2009	Jun	NEWA
AB	ZYDUS PHARMS USA INC	50MG	N79089 001	Jul 06, 2009	Jun	NEWA
	CASODEX					
AB	+ ASTRAZENECA	50MG	N20498 001	Oct 04, 1995	Jun	CFTG

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	TEVA PARENTERAL	0.2%	N76372 001	Sep 10, 2004	Apr	CAHN
----	-----------------	------	------------	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

CYCLOSET

+ VEROSCIENCE	EQ 0.8MG BASE	N20866 001	May 05, 2009	May	NEWA
---------------	---------------	------------	--------------	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

+ MORTON GROVE	2MG/5ML; 10MG/5ML; 30MG/5ML	N88811 001	Jun 07, 1985	Jun	CTNA
@ WOCKHARDT EU	2MG/5ML; 10MG/5ML; 30MG/5ML	N89681 001	Dec 22, 1988	Jun	DISC
AA	2MG/5ML; 10MG/5ML; 30MG/5ML	N89681 001	Dec 22, 1988	Apr	CAHN

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

AN	APOTEX	0.25MG/2ML	N78202	001	Mar 30, 2009	Mar	NEWA
AN		0.5MG/2ML	N78202	002	Mar 30, 2009	Mar	NEWA
AN	TEVA PARENTERAL	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN
AN		0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SENSORCAINE

AP	APP PHARMS	0.25%	N70552	001	May 21, 1986	Jun	CAHN
AP		0.5%	N70553	001	May 21, 1986	Jun	CAHN
AP		0.75%	N70554	001	May 21, 1986	Jun	CAHN

INJECTABLE; SPTNAT

SENSORCAINE

AP APP PHARMS 0.75% N71202 001 Apr 15, 1987 Jun CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SENSORCATINE

AP APP PHARMS 0.25%;0.0091MG/ML N70966 001 Oct 13, 1987 Jun CAHN
 AP 0.25%;0.0091MG/ML N70967 001 Oct 13, 1987 Jun CAHN
 AP 0.5%;0.0091MG/ML N70968 001 Oct 13, 1987 Jun CAHN

BUPROPTON HYDROCHLORIDE

TABLET EXTENDED RELEASE: ORAL

BURBORTON HYDROCHLORIDE

AB1	WATSON LABS	100MG	N79095	001	Mar 24,	2009	Mar	NEWA
AB2		150MG	N79094	001	Mar 24,	2009	Mar	NEWA
AB1		150MG	N79095	002	Mar 24,	2009	Mar	NEWA
AB1		200MG	N79095	003	Mar 24,	2009	Mar	NEWA

WELLBUTRIN XT

>A>	AB3	+	BIOVAIL LABS INTL	150MG	N21515	001	Aug 28, 2003	Jul	CAHN
>A>	AB3			300MG	N21515	002	Aug 28, 2003	Jul	CAHN
>D>	AB3	+	SMITHKLINE BEECHAM	150MG	N21515	001	Aug 28, 2003	Jul	CAHN
>D>	AB3			300MG	N21515	002	Aug 28, 2003	Jul	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSHAR

AB + BRISTOL MYERS SQUIBB 15MG N18731 003 Apr 22, 1996 Feb CRLD
@ 30MG N18731 004 Apr 22, 1996 Feb DISC

BUSPIRONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	N78246	001	Feb 27, 2009	Feb	NEWA
AB		10MG	N78246	002	Feb 27, 2009	Feb	NEWA
AB		15MG	N78246	003	Feb 27, 2009	Feb	NEWA

AB	MYLAN	5MG	N75467	001	Feb 28,	2002	Apr	CAHN
AB		7.5MG	N75467	002	Mar 28,	2001	Apr	CAHN
AB		10MG	N75467	003	Feb 28,	2002	Apr	CAHN

@ SANDOZ 5MG N75413 001 Mar 19, 2002 Mar DISC
 @ 10MG N75413 002 Mar 19, 2002 Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HIKMA FARMACEUTICA	1MG/ML	N78400 001	May 01, 2009	Apr	NEWA
AP		2MG/ML	N78247 001	Apr 29, 2009	Apr	NEWA
AP		2MG/ML	N78400 002	May 01, 2009	Apr	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

AP	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006	Apr	CAHN
----	--------------	---------------------------------------	------------	--------------	-----	------

CALCITONIN, SALMON

SPRAY, METERED; NASAL

CALCITONIN-SALMON

AB	MDRNA	200 IU/SPRAY	N76979 001	Jun 08, 2009	May	NEWA
----	-------	--------------	------------	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

ROCALTROL

AB	VALIDUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
----	----------------	---------	------------	--	-----	------

AB	+	0.5UGM	N18044 002		Mar	CAHN
----	---	--------	------------	--	-----	------

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP

3UGM/GM

N22087 001 Jan 23, 2009 Jan NEWA

SOLUTION; ORAL

ROCALTROL

AA	+	VALIDUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN
----	---	----------------	---------	------------	--------------	-----	------

CAPECITABINE

TABLET; ORAL

XELODA

>D>	HLR	150MG	N20896 001	Apr 30, 1998	Jul	CAHN
-----	-----	-------	------------	--------------	-----	------

>D>	+	500MG	N20896 002	Apr 30, 1998	Jul	CAHN
-----	---	-------	------------	--------------	-----	------

>A>	HOFFMANN LA ROCHE	150MG	N20896 001	Apr 30, 1998	Jul	CAHN
-----	-------------------	-------	------------	--------------	-----	------

>A>	+	500MG	N20896 002	Apr 30, 1998	Jul	CAHN
-----	---	-------	------------	--------------	-----	------

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	N77272 001	Dec 07, 2005	Apr	CAHN
		200MG	N77272 002	Dec 07, 2005	Apr	CAHN
		300MG	N77272 003	Dec 07, 2005	Apr	CAHN
		400MG	N77272 004	Dec 07, 2005	Apr	CAHN

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	N75712 001	Jul 05, 2001	Jan	CAHN
----	----------------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	N78115 001	Mar 31, 2009	Mar	NEWA
AB		200MG	N78115 002	Mar 31, 2009	Mar	NEWA
AB		400MG	N78115 003	Mar 31, 2009	Mar	NEWA
	TEGRETOL-XR					
AB	NOVARTIS	100MG	N20234 001	Mar 25, 1996	Mar	CFTG

TABLET, EXTENDED RELEASE; ORAL

TEGRETOL-XR

AB	NOVARTIS	200MG	N20234 002	Mar 25, 1996	Mar	CFTG
AB	+	400MG	N20234 003	Mar 25, 1996	Mar	CFTG

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

@ PFIZER EQ 382MG BASE

N50435 001 Mar DISC

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

@ SANDOZ	10MG;100MG	N73586 001	Jun 29, 1995	Mar	DISC
@	25MG;100MG	N73587 001	Jun 29, 1995	Mar	DISC
@	25MG;250MG	N73620 001	Jun 29, 1995	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

@ KV PHARM 50MG;200MG

N76663 001 Jun 24, 2004 Apr DISC

>D> TABLET, FOR SUSPENSION; ORAL

CARBILEV

>D>	RANBAXY	10MG;100MG	N76643 001	Jun 10, 2005	Jul	DISC
>A>	@	10MG;100MG	N76643 001	Jun 10, 2005	Jul	DISC
>D>		25MG;100MG	N76643 002	Jun 10, 2005	Jul	DISC
>A>	@	25MG;100MG	N76643 002	Jun 10, 2005	Jul	DISC
>D>	+	25MG;250MG	N76643 003	Jun 10, 2005	Jul	DISC
>A>	@	25MG;250MG	N76643 003	Jun 10, 2005	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

>A> AB	SUN PHARM INDS	10MG;100MG	N78690 001	Jul 31, 2009	Jul	NEWA
>A> AB		25MG;100MG	N78690 002	Jul 31, 2009	Jul	NEWA
>A> AB		25MG;250MG	N78690 003	Jul 31, 2009	Jul	NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	+	WATSON LABS	50MG/VIAL	N76162 001	Oct 14, 2004	Apr	CAHN
AP	+		150MG/VIAL	N76162 002	Oct 14, 2004	Apr	CAHN
AP	+		450MG/VIAL	N76162 003	Oct 14, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>D>	@ ABRAXIS PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Jul	CPOT
>A>	@	50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Jul	CPOT
>D> AP		EQ 50MG/5ML (10MG/ML)	N77266 001	Feb 15, 2006	Jul	CPOT
>A> AP		50MG/5ML (10MG/ML)	N77266 001	Feb 15, 2006	Jul	CPOT
>D>	@	EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Jul	CPOT
>A>	@	150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Jul	CPOT
>D> AP		EQ 150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jul	CPOT
>A> AP		150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jul	CPOT
>D> AP		EQ 450MG/45ML (10MG/ML)	N77247 003	Oct 21, 2004	Jul	CPOT
>A> AP		450MG/45ML (10MG/ML)	N77247 003	Oct 21, 2004	Jul	CPOT
>D> AP		EQ 450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jul	CPOT
>A> AP		450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jul	CPOT
>D> AP		EQ 600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jul	CPOT
>A> AP		600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jul	CPOT
>A> AP	AKORN	50MG/5ML (10MG/ML)	N90475 001	Jul 29, 2009	Jul	NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	AP	AKORN	150MG/15ML (10MG/ML)	N90475 002	Jul 29, 2009	Jul	NEWA
>A>	AP		450MG/45ML (10MG/ML)	N90475 003	Jul 29, 2009	Jul	NEWA
>D>	AP	BEDFORD LABS	EQ 50MG/5ML (10MG/ML)	N77244 001	Oct 15, 2004	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77244 001	Oct 15, 2004	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77244 002	Oct 15, 2004	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77244 002	Oct 15, 2004	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77244 003	Oct 15, 2004	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77244 003	Oct 15, 2004	Jul	CPOT
>D>	AP		EQ 600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jul	CPOT
>A>	AP		600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jul	CPOT
>D>	AP	EBEWE PHARMA	EQ 50MG/5ML (10MG/ML)	N78280 001	May 08, 2008	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N78280 001	May 08, 2008	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N78280 002	May 08, 2008	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N78280 002	May 08, 2008	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N78280 003	May 08, 2008	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N78280 003	May 08, 2008	Jul	CPOT
>D>	AP	FRESENIUS KABI ONCOL	EQ 150MG/15ML (10MG/ML)	N77432 002	Sep 29, 2006	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77432 003	Sep 29, 2006	Jul	CPOT
>D>	AP		EQ 50MG/5ML (10MG/ML)	N77432 001	Sep 29, 2006	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77432 002	Sep 29, 2006	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77432 003	Sep 29, 2006	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77432 001	Sep 29, 2006	Jul	CPOT
>D>	AP	GENERAMEDIX	EQ 50MG/5ML (10MG/ML)	N77998 001	Apr 24, 2007	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77998 001	Apr 24, 2007	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77998 002	Apr 24, 2007	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77998 002	Apr 24, 2007	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77998 003	Apr 24, 2007	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77998 003	Apr 24, 2007	Jul	CPOT
>D>	AP	HOSPIRA	EQ 50MG/5ML (10MG/ML)	N76517 001	Oct 14, 2004	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N76517 001	Oct 14, 2004	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N76517 002	Oct 14, 2004	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N76517 002	Oct 14, 2004	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N76517 003	Oct 14, 2004	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N76517 003	Oct 14, 2004	Jul	CPOT
>D>	AP		EQ 600MG/60ML (10MG/ML)	N77059 001	Nov 23, 2004	Jul	CPOT
>A>	AP		600MG/60ML (10MG/ML)	N77059 001	Nov 23, 2004	Jul	CPOT
>D>	AP	PHARMACHEMIE	EQ 50MG/5ML (10MG/ML)	N77269 001	Oct 14, 2004	Jul	CPOT
>A>	AP	+	50MG/5ML (10MG/ML)	N77269 001	Oct 14, 2004	Jul	CPOT
>D>	AP	+	EQ 150MG/15ML (10MG/ML)	N77269 002	Oct 14, 2004	Jul	CPOT
>A>	AP	+	150MG/15ML (10MG/ML)	N77269 002	Oct 14, 2004	Jul	CPOT
>D>	AP	+	EQ 450MG/45ML (10MG/ML)	N77269 003	Oct 14, 2004	Jul	CPOT
>A>	AP	+	450MG/45ML (10MG/ML)	N77269 003	Oct 14, 2004	Jul	CPOT
>D>	AP	+	EQ 600MG/60ML (10MG/ML)	N77269 004	Dec 28, 2007	Jul	CPOT
>A>	AP	+	600MG/60ML (10MG/ML)	N77269 004	Dec 28, 2007	Jul	CPOT
>D>	AP	PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Jul	CPOT
	AP		EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Feb	NEWA
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Jul	CPOT
	AP		EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Feb	NEWA
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Jul	CPOT
	AP		EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Feb	NEWA
>D>	AP	PLIVA LACHEMA	EQ 50MG/5ML (10MG/ML)	N78631 001	Dec 02, 2008	Jul	CPOT

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	N78631	001	Dec 02,	2008	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N78631	002	Dec 02,	2008	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N78631	002	Dec 02,	2008	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N78631	003	Dec 02,	2008	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N78631	003	Dec 02,	2008	Jul	CPOT
>D>	AP		EQ 600MG/60ML (10MG/ML)	N78631	004	Dec 02,	2008	Jul	CPOT
>A>	AP		600MG/60ML (10MG/ML)	N78631	004	Dec 02,	2008	Jul	CPOT
>D>	AP	SPECTRUM PHARMS	EQ 50MG/5ML (10MG/ML)	N77096	001	Jun 14,	2005	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77096	001	Jun 14,	2005	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77096	002	Jun 14,	2005	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77096	002	Jun 14,	2005	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77096	003	Jun 14,	2005	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77096	003	Jun 14,	2005	Jul	CPOT
>D>	AP	SUN PHARM INDS	EQ 50MG/5ML (10MG/ML)	N77926	001	Sep 19,	2008	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77926	001	Sep 19,	2008	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77926	002	Sep 19,	2008	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77926	002	Sep 19,	2008	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77926	003	Sep 19,	2008	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77926	003	Sep 19,	2008	Jul	CPOT
>D>	AP	+ TEVA PARENTERAL	EQ 50MG/5ML (10MG/ML)	N77139	001	Sep 21,	2005	Jul	CPOT
>A>	AP	+	50MG/5ML (10MG/ML)	N77139	001	Sep 21,	2005	Jul	CPOT
>D>	AP		EQ 50MG/5ML (10MG/ML)	N77389	001	Mar 30,	2007	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77389	001	Mar 30,	2007	Jul	CPOT
>D>	AP	+	EQ 150MG/15ML (10MG/ML)	N77139	002	Sep 21,	2005	Jul	CPOT
>A>	AP	+	150MG/15ML (10MG/ML)	N77139	002	Sep 21,	2005	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77389	002	Mar 30,	2007	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77389	002	Mar 30,	2007	Jul	CPOT
>D>	AP	+	EQ 450MG/45ML (10MG/ML)	N77139	003	Sep 21,	2005	Jul	CPOT
>A>	AP	+	450MG/45ML (10MG/ML)	N77139	003	Sep 21,	2005	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77389	003	Mar 30,	2007	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77389	003	Mar 30,	2007	Jul	CPOT
>D>	AP	+	EQ 450MG/45ML (10MG/ML)	N77389	003	Mar 30,	2007	Jul	CPOT
>A>	AP	+	600MG/60ML (10MG/ML)	N77139	004	Sep 21,	2005	Jul	CPOT
>D>	AP		600MG/60ML (10MG/ML)	N77139	004	Sep 21,	2005	Jul	CPOT
>A>	AP	+	600MG/60ML (10MG/ML)	N77139	004	Sep 21,	2005	Jul	CPOT
>D>	AP	WATSON LABS	EQ 50MG/5ML (10MG/ML)	N77861	001	Jan 18,	2007	Jul	CPOT
>A>	AP		50MG/5ML (10MG/ML)	N77861	001	Jan 18,	2007	Jul	CPOT
>D>	AP		EQ 150MG/15ML (10MG/ML)	N77861	002	Jan 18,	2007	Jul	CPOT
>A>	AP		150MG/15ML (10MG/ML)	N77861	002	Jan 18,	2007	Jul	CPOT
>D>	AP		EQ 450MG/45ML (10MG/ML)	N77861	003	Jan 18,	2007	Jul	CPOT
>A>	AP		450MG/45ML (10MG/ML)	N77861	003	Jan 18,	2007	Jul	CPOT
>D>	AP		EQ 600MG/60ML (10MG/ML)	N77861	004	Jan 18,	2007	Jul	CPOT
>A>	AP		600MG/60ML (10MG/ML)	N77861	004	Jan 18,	2007	Jul	CPOT
		PARAPLATIN							
>D>	AP	+ BRISTOL MYERS SQUIBB	EQ 50MG/5ML (10MG/ML)	N20452	001	Jul 14,	2003	Jul	CPOT
>A>	AP	+	50MG/5ML (10MG/ML)	N20452	001	Jul 14,	2003	Jul	CPOT
>D>	AP	+	EQ 150MG/15ML (10MG/ML)	N20452	002	Jul 14,	2003	Jul	CPOT
>A>	AP	+	150MG/15ML (10MG/ML)	N20452	002	Jul 14,	2003	Jul	CPOT
>D>	AP	+	EQ 450MG/45ML (10MG/ML)	N20452	003	Jul 14,	2003	Jul	CPOT
>A>	AP	+	450MG/45ML (10MG/ML)	N20452	003	Jul 14,	2003	Jul	CPOT
>D>	AP	+	EQ 600MG/60ML (10MG/ML)	N20452	004	Jan 15,	2004	Jul	CPOT
>A>	AP	+	600MG/60ML (10MG/ML)	N20452	004	Jan 15,	2004	Jul	CPOT

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>A>	AA	AUROBINDO PHARMA @ SANDOZ	350MG 350MG	N40792 001 Aug 06, 2009 Jul NEWA N81025 001 Apr 13, 1989 Mar DISC
-----	----	------------------------------	----------------	--

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

@ GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N50461 003

Jun DISC

@

EQ 10GM BASE/VIAL

N50461 005

Jun DISC

CEFAZOLIN SODIUM

AP CEPHAZONE PHARMA

EQ 500MG BASE/VIAL

N65280 001 Mar 18, 2009 Mar NEWA

AP EQ 1GM BASE/VIAL

N65280 002 Mar 18, 2009 Mar NEWA

AP EQ 10GM BASE/VIAL

N65295 001 Mar 18, 2009 Mar NEWA

AP EQ 20GM BASE/VIAL

N65296 001 Mar 18, 2009 Mar NEWA

@ GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N64033 001 Oct 31, 1993 Mar DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP ACS DOBFAR

EQ 1GM BASE/VIAL

N65414 001 Jun 12, 2009 Jun NEWA

AP EQ 2GM BASE/VIAL

N65414 002 Jun 12, 2009 Jun NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

TAZICEF

@ HOSPIRA

1GM/VIAL

N64032 001 Oct 31, 1993 Jul CMFD

>D>

AP 1GM/VIAL

N64032 001 Oct 31, 1993 Jul CMFD

>D>

@

2GM/VIAL

N64032 002 Oct 31, 1993 Jul CMFD

>A>

AP 2GM/VIAL

N64032 002 Oct 31, 1993 Jul CMFD

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

>D> AP SANDOZ

EQ 250MG BASE/VIAL

N65169 001 May 09, 2005 Jul CRLD

>A>

AP + EQ 250MG BASE/VIAL

N65169 001 May 09, 2005 Jul CRLD

>D>

AP EQ 500MG BASE/VIAL

N65169 002 May 09, 2005 Jul CRLD

>A>

AP + EQ 500MG BASE/VIAL

N65169 002 May 09, 2005 Jul CRLD

>D>

AP EQ 1GM BASE/VIAL

N65169 003 May 09, 2005 Jul CRLD

>A>

AP + EQ 1GM BASE/VIAL

N65169 003 May 09, 2005 Jul CRLD

AP +

EQ 2GM BASE/VIAL

N65169 004 May 09, 2005 Mar CRLD

ROCEPHIN

@ HLR

EQ 250MG BASE/VIAL

N50585 001 Dec 21, 1984 Jul CAHN

>D>

@

EQ 500MG BASE/VIAL

N50585 002 Dec 21, 1984 Jul CAHN

>D>

@

EQ 1GM BASE/VIAL

N50585 003 Dec 21, 1984 Jul CAHN

>D>

@

EQ 2GM BASE/VIAL

N50585 004 Dec 21, 1984 Jul CAHN

>A>

@ HOFFMANN LA ROCHE

EQ 250MG BASE/VIAL

N50585 001 Dec 21, 1984 Jul CAHN

>A>

@

EQ 500MG BASE/VIAL

N50585 002 Dec 21, 1984 Jul CAHN

>A>

@

EQ 1GM BASE/VIAL

N50585 003 Dec 21, 1984 Jul CAHN

>A>

@

EQ 2GM BASE/VIAL

N50585 004 Dec 21, 1984 Jul CAHN

INJECTABLE; INJECTION

ROCEPHIN

@ HLR

EQ 10GM BASE/VIAL

N50585 005 Dec 21, 1984 Jul CAHN

>A>

@ HOFFMANN LA ROCHE

EQ 10GM BASE/VIAL

N50585 005 Dec 21, 1984 Jul CAHN

INJECTABLE; INJECTION

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

>D>	@ HLR	EQ 10MG BASE/ML	N50624 001	Feb 11, 1987	Jul	CAHN
>D>	@	EQ 20MG BASE/ML	N50624 002	Feb 11, 1987	Jul	CAHN
>D>	@	EQ 40MG BASE/ML	N50624 003	Feb 11, 1987	Jul	CAHN
>A>	@ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N50624 001	Feb 11, 1987	Jul	CAHN
>A>	@	EQ 20MG BASE/ML	N50624 002	Feb 11, 1987	Jul	CAHN
>A>	@	EQ 40MG BASE/ML	N50624 003	Feb 11, 1987	Jul	CAHN

CEFTRIAXONE SODIUM; LIDOCAINEINJECTABLE; INJECTION

ROCEPHIN KIT

>D>	@ HLR	EQ 500MG BASE/VIAL,N/A;N/A,1%	N50585 007	May 08, 1996	Jul	CAHN
>D>	@	EQ 1GM BASE/VIAL,N/A;N/A,1%	N50585 006	May 08, 1996	Jul	CAHN
>A>	@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N50585 007	May 08, 1996	Jul	CAHN
>A>	@	EQ 1GM BASE/VIAL,N/A;N/A,1%	N50585 006	May 08, 1996	Jul	CAHN

CETIRIZINE HYDROCHLORIDESYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	DR REDDYS LABS LTD	5MG/5ML	N78870 001	Apr 27, 2009	Apr	NEWA
----	--------------------	---------	------------	--------------	-----	------

CHLORHEXIDINE GLUCONATESOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	XTTRIUM	0.12%	N77789 001	Jun 18, 2009	Jun	NEWA
----	---------	-------	------------	--------------	-----	------

CHLOROTHIAZIDETABLET; ORAL

DIURIL

@ LUNDBECK INC	250MG	N11145 004	Apr	CAHN
@	500MG	N11145 002	Apr	CAHN

CHLOROTHIAZIDE SODIUMINJECTABLE; INJECTION

DIURIL

+ LUNDBECK INC	EQ 500MG BASE/VIAL	N11145 005	Apr	CAHN
----------------	--------------------	------------	-----	------

CHLORPROPAMIDETABLET; ORAL

CHLORPROPAMIDE

@ SANDOZ	100MG	N88725 001	Aug 31, 1984	Mar	DISC
@	250MG	N88726 001	Aug 31, 1984	Mar	DISC

CHLORZOXAZONETABLET; ORAL

CHLORZOXAZONE

@ SANDOZ	250MG	N89852 001	May 04, 1988	Mar	DISC	
@	500MG	N89853 001	May 04, 1988	Mar	DISC	
AA	WATSON LABS	500MG	N89859 001	May 04, 1988	Apr	CAHN

CHOLINE FENOFLIBRATECAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

ABBOTT LABS	EQ 45MG FENOFLIBRIC ACID	N22224 001	Dec 15, 2008	Jan	CTNA
+	EQ 135MG FENOFLIBRIC ACID	N22224 002	Dec 15, 2008	Jan	CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

@ CHART MEDCL	4,000 UNITS/VIAL	N18663 002 Aug 21, 1984 Mar CAHN
@	10,000 UNITS/VIAL	N18663 001 Nov 10, 1982 Mar CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ SANDOZ	200MG	N74100 001 Jan 31, 1995 Mar DISC
@	300MG	N74100 002 Jan 31, 1995 Mar DISC
@	400MG	N74100 003 Jan 31, 1995 Mar DISC
@	800MG	N74100 004 Jan 31, 1995 Mar DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OTIC

CETRAXAL

>D>	+ LABORATORIOS SALVAT	EQ 0.2% BASE	N21918 001 May 01, 2009 Jul CAHN
	+	EQ 0.2% BASE	N21918 001 May 01, 2009 May NEWA
>A>	+ WRASER PHARMS	EQ 0.2% BASE	N21918 001 May 01, 2009 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	N75685 002 Jun 09, 2004 Mar CMFD
AB		EQ 500MG BASE	N75685 003 Jun 09, 2004 Mar CMFD
AB		EQ 750MG BASE	N75685 001 Jun 09, 2004 Mar CMFD
	@ TEVA	EQ 250MG BASE	N76136 001 Jun 09, 2004 Jan DISC
	@	EQ 500MG BASE	N76136 002 Jun 09, 2004 Jan DISC
	@	EQ 750MG BASE	N76136 003 Jun 09, 2004 Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS	EQ 10MG BASE	N77045 003 Apr 29, 2005 Feb CAHN
AB		EQ 20MG BASE	N77045 002 Apr 29, 2005 Feb CAHN
AB		EQ 40MG BASE	N77045 001 Apr 29, 2005 Feb CAHN
AB	GLENMARK GENERICS	EQ 10MG BASE	N77654 001 Feb 27, 2009 Feb NEWA
AB		EQ 20MG BASE	N77654 002 Feb 27, 2009 Feb NEWA
AB		EQ 40MG BASE	N77654 003 Feb 27, 2009 Feb NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

>D>	+ RANBAXY	1GM	N65210 001 Jan 26, 2005 Jul DISC
>A>	@	1GM	N65210 001 Jan 26, 2005 Jul DISC

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+	DOW PHARM SCIENCES	0.1%	N17765 001 Jun CAHN
---	--------------------	------	---------------------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>D> AB	KALI LABS	0.5MG	N77147 001 May 02, 2005 Jul DISC
>A>	@	0.5MG	N77147 001 May 02, 2005 Jul DISC

TABLET; ORAL

CLONAZEPAM

>D>	AB	KALI LABS	1MG	N77147	002	May 02,	2005	Jul	DISC
>A>		@	1MG	N77147	002	May 02,	2005	Jul	DISC
>D>	AB		2MG	N77147	003	May 02,	2005	Jul	DISC
>A>		@	2MG	N77147	003	May 02,	2005	Jul	DISC

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ SANDOZ	0.1MG	N70887	001	Aug 31,	1988	Mar	DISC
@	0.2MG	N70886	001	Aug 31,	1988	Mar	DISC
@	0.3MG	N71294	001	Aug 31,	1988	Mar	DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

@ DR REDDYS LABS INC	EQ 75MG BASE	N76273	001	Jan 14,	2008	Jun	DISC
PLAVIX							
SANOFI AVENTIS US	EQ 75MG BASE	N20839	001	Nov 17,	1997	Jun	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ	3.75MG	N72219	001	Aug 26,	1988	Mar	DISC
TRANXENE							
@ LUNDBECK INC	3.75MG	N17105	001			Apr	CAHN
@	7.5MG	N17105	002			Apr	CAHN
@	15MG	N17105	003			Apr	CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ	7.5MG	N72513	001	May 11,	1990	Mar	DISC
@	15MG	N72514	001	May 11,	1990	Mar	DISC

TRANXENE

AB	LUNDBECK INC	3.75MG	N17105	006		Apr	CAHN
AB		7.5MG	N17105	007		Apr	CAHN
AB	+	15MG	N17105	008		Apr	CAHN
	TRANXENE SD						
	@ LUNDBECK INC	11.25MG	N17105	005		May	DISC
		11.25MG	N17105	005		Apr	CAHN
	@	22.5MG	N17105	004		May	DISC
	+	22.5MG	N17105	004		Apr	CAHN

CLOXAICILLIN SODIUM

CAPSULE; ORAL

CLOXAPEN

@ GLAXOSMITHKLINE	EQ 250MG BASE	N61806	001			Jun	DISC
@	EQ 500MG BASE	N61806	002			Jun	DISC

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704	001	Mar 22,	1985	Apr	CAHN
------------------	------------------------------	--------	-----	---------	------	-----	------

CODEINE SULFATE

>A>	TABLET; ORAL						
>A>	CODEINE SULFATE						
>A>	ROXANE	15MG		N22402	001	Jul 16, 2009	Jul NEWA
>A>		30MG		N22402	002	Jul 16, 2009	Jul NEWA
>A>	+	60MG		N22402	003	Jul 16, 2009	Jul NEWA

COLCHICINE

	TABLET; ORAL						
	COLCRYS						
>A>	+	AR HOLDING CO INC	0.6MG	N22352	001	Jul 29, 2009	Jul CAHN

COLISTIMETHATE SODIUM

	INJECTABLE; INJECTION						
	COLISTIMETHATE SODIUM						
AP	PADDOCK	EQ 150MG BASE/VIAL		N65177	001	Mar 19, 2004	Apr CTNA
AP	X GEN PHARMS	EQ 150MG BASE/VIAL		N64216	001	Feb 26, 1999	Apr CTNA

CROMOLYN SODIUM

	SOLUTION; INHALATION						
	CROMOLYN SODIUM						
AN	+	TEVA PARENTERAL	10MG/ML	N75271	001	Jan 18, 2000	Apr CAHN

CYANOCOBALAMIN

	GEL, METERED; NASAL						
	NASCOBAL						
	@ PAR PHARM	0.5MG/INH		N19722	001	Nov 05, 1996	Mar CAHN
	SPRAY, METERED; NASAL						
	NASCOBAL						
	+	PAR PHARM CO	0.5MG/SPRAY	N21642	001	Jan 31, 2005	May CAHN

CYCLOPHOSPHAMIDE

	INJECTABLE; INJECTION						
	CYTOXAN						
	@ BAXTER HLTHCARE	100MG/VIAL		N12142	001	Feb	CAHN
	@	200MG/VIAL		N12142	002	Feb	CAHN
	@	500MG/VIAL		N12142	003	Feb	CAHN
	@	1GM/VIAL		N12142	004	Aug 30, 1982	Feb CAHN
	@	2GM/VIAL		N12142	005	Aug 30, 1982	Feb CAHN
	LYOPHILIZED CYTOXAN						
	+	BAXTER HLTHCARE	100MG/VIAL	N12142	006	Dec 05, 1985	Feb CAHN
	+		200MG/VIAL	N12142	007	Dec 10, 1985	Feb CAHN
AP	+		500MG/VIAL	N12142	008	Jan 04, 1984	Feb CAHN
AP	+		1GM/VIAL	N12142	010	Sep 24, 1985	Feb CAHN
AP	+		2GM/VIAL	N12142	009	Dec 10, 1984	Feb CAHN
	TABLET; ORAL						
	CYTOXAN						
	@ BAXTER HLTHCARE	25MG		N12141	002	Feb	CAHN
	@	50MG		N12141	001	Feb	CAHN

DACTINOMYCIN

	INJECTABLE; INJECTION						
	COSMEGEN						
	+	LUNDBECK INC	0.5MG/VIAL	N50682	001	Apr	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

>A>	CENTOCOR ORTHO	EQ 75MG BASE	N21976 004	Dec 18, 2008	Jul	CAHN
>A>		EQ 150MG BASE	N21976 005	Dec 18, 2008	Jul	CAHN
>A>		EQ 300MG BASE	N21976 001	Jun 23, 2006	Jul	CAHN
>A>		EQ 400MG BASE	N21976 003	Oct 21, 2008	Jul	CAHN
>A>	+	EQ 600MG BASE	N21976 002	Feb 25, 2008	Jul	CAHN
>D>	TIBOTEC	EQ 75MG BASE	N21976 004	Dec 18, 2008	Jul	CAHN
>D>		EQ 150MG BASE	N21976 005	Dec 18, 2008	Jul	CAHN
>D>		EQ 150MG BASE	N21976 005	Dec 18, 2008	Jun	CMFD
>D>		EQ 300MG BASE	N21976 001	Jun 23, 2006	Jul	CAHN
>D>		EQ 400MG BASE	N21976 003	Oct 21, 2008	Jul	CAHN
>D>	+	EQ 600MG BASE	N21976 002	Feb 25, 2008	Jul	CAHN

DAUNORUBICIN CITRATE

>D>	INJECTABLE, LIPOSOMAL; INJECTION					
>D>	DAUNOXOME					
>D>	+	DIATOS	EQ 2MG BASE/ML	N50704 002	Apr 08, 1996	Jul DISC
>A>	@		EQ 2MG BASE/ML	N50704 002	Apr 08, 1996	Jul DISC

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	WATSON LABS	500MG/VIAL	N76806 001	Mar 31, 2006	Apr	CAHN
AP		2GM/VIAL	N76806 002	Mar 31, 2006	Apr	CAHN

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

FERRING

EQ 80MG BASE/VIAL

N22201 001 Dec 24, 2008 Jun CTNA

+

EQ 120MG BASE/VIAL

N22201 002 Dec 24, 2008 Jun CTNA

DESOGESTREL; ETHINYLL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYLL ESTRADIOL

@ DURAMED PHARMS BARR 0.15MG;0.03MG

N75256 001 Aug 12, 1999 Feb DISC

DESVENLAFAKINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

PRISTIQ

>D>	WYETH PHARMS INC	EQ 50MG BASE	N21992 001	Feb 29, 2008	Jul	CRLD
>A>	+	EQ 50MG BASE	N21992 001	Feb 29, 2008	Jul	CRLD

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	+	STI PHARMA LLC	0.5MG/5ML	N84754 001	Apr	CAHN
		IMPLANT; INTRAVITREAL				
		OZURDEX				
	+	ALLERGAN	0.7MG	N22315 001	Jun 17, 2009	Jun NEWA

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC
 TOBRADEX ST
 + ALCON 0.05%;0.3% N50818 001 Feb 13, 2009 Feb NEWA

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
 KAPIDEX
 TAKEDA PHARMS 30MG N22287 001 Jan 30, 2009 Jan NEWA
 + 60MG N22287 002 Jan 30, 2009 Jan NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
 DEXTROAMPHETAMINE SULFATE
 AA + BARR 10MG N40361 002 Jan 31, 2001 Mar CRLD
 DEXTROSTAT
 @ SHIRE 5MG N84051 001 Mar DISC
 @ 10MG N84051 002 Mar DISC

DEXTROSE

INJECTABLE; INJECTION
 DEXTROSE 60% IN PLASTIC CONTAINER
 @ HOSPIRA 60GM/100ML N19346 001 Jan 25, 1985 Apr DISC

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
 RENO-60
 @ BRACCO 60% N10040 016 Jun DISC
 RENO-DIP
 @ BRACCO 30% N10040 012 Jun DISC
 SOLUTION; URETERAL
 RENO-30
 @ BRACCO 30% N10040 021 Jun DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
 RENOGRAFIN-60
 @ BRACCO 52%;8% N10040 006 Jun DISC

DIAZEPAM

TABLET; ORAL
 DIAZEPAM
 @ SANDOZ 2MG N70302 001 Dec 20, 1985 Mar DISC
 @ 5MG N70303 001 Dec 20, 1985 Mar DISC
 @ 10MG N70304 001 Dec 20, 1985 Mar DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL
 ZIPSOR
 + XANODYNE PHARM 25MG N22202 001 Jun 18, 2009 Jun NEWA
 FOR SOLUTION; ORAL
 CAMBIA
 + KOWA PHARMS 50MG N22165 001 Jun 17, 2009 Jun NEWA

DIETHYLPROMION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROMION HYDROCHLORIDE

AA	COREPHARMA	25MG	N40828 001 Nov 05, 2008 Feb CTEC
	TENUATE		
AA +	WATSON PHARMS	25MG	N11722 002 Feb CTEC

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ SANDOZ 500MG

+ TEVA 500MG

N74604 001 Jun 10, 1996 Mar DISC

N73673 001 Jul 31, 1992 Mar CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

@ HOSPIRA 0.25MG/ML

N40206 001 Aug 28, 1998 Apr DISC

TABLET; ORAL

DIGOXIN

AB	IMPAK LABS	0.125MG	N78556 001 Jul 20, 2009 Jun NEWA
AB		0.25MG	N78556 002 Jul 20, 2009 Jun NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILT-CD

AB3	APOTEX	300MG	N76151 004 May 20, 2004 Apr CAHN
	DILTIAZEM HYDROCHLORIDE		
>D>	+ MYLAN	120MG	N74910 003 May 02, 1997 Jul CTEC

>A>	BC +	120MG	N74910 003 May 02, 1997 Jul CTEC
-----	------	-------	----------------------------------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	N80738 001 Mar CRLD
@	LNK	25MG	N87977 001 Jan 27, 1983 Mar DISC
@		50MG	N87978 001 Jan 27, 1983 Mar DISC
@	SANDOZ	25MG	N80832 001 Mar DISC
@		50MG	N80832 002 Mar DISC
@	VALEANT PHARM INTL	50MG	N80592 001 Mar DISC
@	WATSON LABS	25MG	N80728 001 Mar DISC
@		50MG	N80727 001 Mar DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ SANDOZ 25MG

@ 50MG

@ 75MG

N86944 002 Apr 16, 1991 Mar DISC

N87562 001 Feb 25, 1992 Mar DISC

N87561 001 Feb 25, 1992 Mar DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB	+ ABBOTT	EQ 125MG VALPROIC ACID	N19680 001 Sep 12, 1989 Jan CFTG
	DIVALPROEX SODIUM		
AB	DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	N78979 001 Jan 23, 2009 Jan NEWA

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB ZYDUS PHARMS USA INC EQ 125MG VALPROIC ACID N78919 001 Jan 27, 2009 Jan NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB MYLAN EQ 125MG VALPROIC ACID N90062 001 Mar 17, 2009 Mar NEWA

AB EQ 250MG VALPROIC ACID N90062 002 Mar 17, 2009 Mar NEWA

AB EQ 500MG VALPROIC ACID N90062 003 Mar 17, 2009 Mar NEWA

AB ZYDUS PHARMS USA INC EQ 125MG VALPROIC ACID N77100 001 Mar 05, 2009 Feb NEWA

AB EQ 250MG VALPROIC ACID N77100 002 Mar 05, 2009 Feb NEWA

AB EQ 500MG VALPROIC ACID N77100 003 Mar 05, 2009 Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

AB ABBOTT EQ 250MG VALPROIC ACID N21168 002 May 31, 2002 Jan CFTG

AB + EQ 500MG VALPROIC ACID N21168 001 Aug 04, 2000 Jan CFTG

DIVALPROEX SODIUM

AB ANCHEN PHARMS EQ 250MG VALPROIC ACID N78445 001 Feb 26, 2009 Feb NEWA

AB EQ 500MG VALPROIC ACID N78445 002 Aug 04, 2009 Jul NEWA

IMPAX LABS

AB EQ 250MG VALPROIC ACID N78791 001 May 06, 2009 Apr NEWA

AB EQ 500MG VALPROIC ACID N78791 002 Aug 04, 2009 Jul NEWA

MYLAN

AB EQ 250MG VALPROIC ACID N77567 001 Jan 29, 2009 Jan NEWA

AB EQ 500MG VALPROIC ACID N77567 002 Jan 29, 2009 Jan NEWA

TEVA PHARMS

AB EQ 500MG VALPROIC ACID N78700 001 Aug 03, 2009 Jul NEWA

WOCKHARDT

AB EQ 250MG VALPROIC ACID N78705 002 Feb 10, 2009 Jan NEWA

AB EQ 500MG VALPROIC ACID N78705 001 Aug 04, 2009 Jul NEWA

ZYDUS PHARMS USA INC

AB EQ 250MG VALPROIC ACID N78239 001 Feb 27, 2009 Feb NEWA

AB EQ 500MG VALPROIC ACID N78239 002 Aug 04, 2009 Jul NEWA

DORIPENEMINJECTABLE; IV (INFUSION)

DORIBAX

+ ORTHO MCNEIL JANSSEN 500MG/VIAL

N22106 001 Oct 12, 2007 Jun CAHN

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT ALCON EQ 2% BASE N78981 001 Apr 13, 2009 Mar NEWA

AT BAUSCH AND LOMB EQ 2% BASE N90143 001 Jun 25, 2009 Jun NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT BAUSCH AND LOMB EQ 2% BASE;EQ 0.5% BASE N90037 001 Jul 14, 2009 Jun NEWA

DOXERCALCIFEROLCAPSULE; ORAL

HECTOROL

>A> GENZYME 1UGM N20862 003 Jul 13, 2009 Jul NEWA

DOXYCYCLINECAPSULE; ORAL

DOXYCYCLINE

+ PAR PHARM EQ 150MG BASE N65055 003 Jul 15, 2005 Jan CRLD

TABLET; ORAL

DOXYCYCLINE

AB MUTUAL PHARM EQ 50MG BASE N65471 001 Apr 17, 2009 Mar NEWA

TABLET; ORAL

DOXYCYCLINE

AB	MUTUAL PHARM	EQ 75MG BASE	N65471 002	Apr 17, 2009	Mar	NEWA
AB		EQ 100MG BASE	N65471 003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB	SVC PHARMA	2.5MG	N78292 001	Jun 27, 2008	Mar	CAHN
AB		5MG	N78292 002	Jun 27, 2008	Mar	CAHN
AB		10MG	N78292 003	Jun 27, 2008	Mar	CAHN

>A> DRONEDARONE HYDROCHLORIDE

>A> TABLET; ORAL

>A> MULTAQ

>A>	+ SANOFI AVENTIS US	EQ 400MG BASE	N22425 001	Jul 01, 2009	Jul	NEWA
-----	---------------------	---------------	------------	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG;0.02MG	N78515 001	Mar 30, 2009	Mar	NEWA
	YAZ					
AB	+ BAYER HLTHCARE	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

AP	BIONICHE PHARMA	10MG/ML	N88873 001	Aug 06, 1985	Jun	CMFD
----	-----------------	---------	------------	--------------	-----	------

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

@ BRISTOL MYERS SQUIBB 100MG

N20972 002 Sep 17, 1998 Jun DISC

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ SANDOZ	2.5MG	N75048 001	Aug 22, 2000	Mar	DISC
@	5MG	N75048 002	Aug 22, 2000	Mar	DISC
@	10MG	N75048 003	Aug 22, 2000	Mar	DISC
@	20MG	N75048 004	Aug 22, 2000	Mar	DISC

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXCEL

@ ASTRAZENECA 5MG;2.5MG

N20668 002 Oct 28, 1998 May DISC

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	+ HOSPIRA	1.25MG/ML	N75458 001	Aug 22, 2000	Feb	CRLD
	VASOTEC					
	@ BIOVAIL LABS INTL	1.25MG/ML	N19309 001	Feb 09, 1988	Feb	DISC

EPINEPHRINE

INJECTABLE; IM-SC TWINJECT 0.15			
+ SCIELE PHARMA INC	EQ 0.15MG /DELIVERY	N20800 002	May 28, 2004 Jun CAHN
TWINJECT 0.3			
+ SCIELE PHARMA INC	EQ 0.3MG /DELIVERY	N20800 001	May 30, 2003 Jun CAHN

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION CITANEST FORTE DENTAL			
+ DENTSPLY PHARM	0.005MG/ML; 4%	N21383 001	Apr CTNA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION XYLOCAINE DENTAL WITH EPINEPHRINE			
AP + DENTSPLY PHARM	0.01MG/ML; 2%	N21381 001	Apr CTNA
AP +	0.02MG/ML; 2%	N21381 002	Apr CTNA
XYLOCAINE W/ EPINEPHRINE			
AP + APP PHARMS	0.02MG/ML; 2%	N06488 005	Apr CMFD

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION EPIRUBICIN HYDROCHLORIDE			
AP AKORN INC	50MG/25ML (2MG/ML)	N90163 001	Jun 24, 2009 Jun NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION EPOPROSTENOL SODIUM			
+ ACTELION	EQ 1.5MG BASE/VIAL	N22260 001	Jun 27, 2008 Apr CAHN

ERGOCALCIFEROL

CAPSULE; ORAL ERGOCALCIFEROL			
AA ORIT LABS LLC	50,000 IU	N40833 001	May 20, 2009 May NEWA

ERYTHROMYCIN

OINTMENT; OPHTHALMIC ERYTHROMYCIN			
>D> AT AKORN	0.5%	N64030 001	Jul 18, 1996 Jul DISC
>A> @	0.5%	N64030 001	Jul 18, 1996 Jul DISC
OINTMENT; TOPICAL AKNE-MYCIN			
+ DOW PHARM SCIENCES	2%	N50584 001	Jan 10, 1985 Jun CAHN
SOLUTION; TOPICAL SANSAC			
>D> @ CORIA	2%	N62522 001	Jan 24, 1985 Jul CAHN
>A> @ DOW PHARM SCIENCES	2%	N62522 001	Jan 24, 1985 Jul CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL ERYTHROMYCIN ESTOLATE			
@ ALPHARMA US PHARMS	EQ 125MG BASE/5ML	N62353 001	Nov 18, 1982 Apr DISC
@	EQ 250MG BASE/5ML	N62409 001	Dec 16, 1982 Apr DISC

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ALPHARMA US PHARMS	EQ 200MG BASE/5ML	N62200 001	Apr	DISC
@	EQ 400MG BASE/5ML	N62200 002	Apr	DISC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001	May 20,	1988	Jun	CMFD
--------	---	------------	---------	------	-----	------

ERYZOLE

@ ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001	Jun 15,	1988	Jan	DISC
--------	---	------------	---------	------	-----	------

PEDIAZOLE

@ ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001	Jan	DISC
-------------	---	------------	-----	------

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

@ HOSPIRA	EQ 1GM BASE/VIAL	N50182 003	Feb	DISC
-----------	------------------	------------	-----	------

AP +	EQ 1GM BASE/VIAL	N62638 002	Oct 31,	1986	Feb	CRLD
------	------------------	------------	---------	------	-----	------

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

>D> AB	FOREST LABS	EQ 5MG BASE	N21323 001	Aug 14,	2002	Jul	CTEC
>A>		EQ 5MG BASE	N21323 001	Aug 14,	2002	Jul	CTEC
>D> AB		EQ 10MG BASE	N21323 002	Aug 14,	2002	Jul	CTEC
>A>		EQ 10MG BASE	N21323 002	Aug 14,	2002	Jul	CTEC
>D> AB	+	EQ 20MG BASE	N21323 003	Aug 14,	2002	Jul	CTEC
>A>	+	EQ 20MG BASE	N21323 003	Aug 14,	2002	Jul	CTEC

ESTRADIOL

TABLET; ORAL

INNOFEM

@ NOVO NORDISK INC	0.5MG	N40312 001	Nov 19,	1999	Apr	DISC
@	1MG	N40312 002	Nov 19,	1999	Apr	DISC
@	2MG	N40312 003	Nov 19,	1999	Apr	DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	LUPIN	100MG	N78939 001	Jun 17,	2009	Jun	NEWA
AB		400MG	N78939 002	Jun 17,	2009	Jun	NEWA
	MYAMBUTOL						
AB	STI PHARMA LLC	100MG	N16320 001			Mar	CAHN
	@	200MG	N16320 002			Mar	CAHN
AB		400MG	N16320 003			Mar	CAHN
	@	500MG	N16320 004			Mar	CAHN

ETHINYLO Estradiol; Ethynodiol Diacetate

TABLET; ORAL-21

DEMULEN 1/35-21

@ GD SEARLE LLC	0.035MG; 1MG	N18168 001	Apr	DISC
-----------------	--------------	------------	-----	------

TABLET; ORAL-21

DEMULEN 1/50-21				
@ GD SEARLE LLC	0.05MG;1MG	N16927	001	Apr DISC
ZOVIA 1/35E-21				
@ WATSON LABS	0.035MG;1MG	N72720	001	Dec 30, 1991 Apr DISC
ZOVIA 1/50E-21				
@ WATSON LABS	0.05MG;1MG	N72722	001	Dec 30, 1991 Apr DISC
TABLET; ORAL-28				
DEMULEN 1/35-28				
@ GD SEARLE LLC	0.035MG;1MG	N18160	001	Apr DISC
DEMULEN 1/50-28				
@ GD SEARLE LLC	0.05MG;1MG	N16936	001	Apr DISC
ZOVIA 1/50E-28				
+ WATSON LABS	0.05MG;1MG	N72723	001	Dec 30, 1991 Apr CRLD

ETHINYLMESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIC-21				
@ AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19192	001	Nov 01, 1984 Apr CAHN

TABLET; ORAL-28

TRIPHASIC-28				
@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190	001	Nov 01, 1984 Apr DISC

ETHINYLMESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYLMESTRADIOL (7/14)				
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991 Apr CRLD

TABLET; ORAL-28

NORETHINDRONE AND ETHINYLMESTRADIOL (10/11)				
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044	001	Apr 01, 1988 Apr CTEC

ETHINYLMESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

LOESTRIN 21 1.5/30				
--------------------	--	--	--	--

AB WARNER CHILCOTT	0.03MG;1.5MG	N17875	001	Apr CRLD
--------------------	--------------	--------	-----	----------

LOESTRIN 21 1/20				
------------------	--	--	--	--

AB WARNER CHILCOTT	0.02MG;1MG	N17876	001	Apr CRLD
--------------------	------------	--------	-----	----------

TABLET; ORAL-28

LOESTRIN FE 1/20				
------------------	--	--	--	--

AB WARNER CHILCOTT	0.02MG;1MG	N17354	001	Apr CRLD
--------------------	------------	--------	-----	----------

ETHINYLMESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO				
---------------------	--	--	--	--

AB + ORTHO MCNEIL JANSSEN	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N21241	001	Aug 22, 2002 Jun CFTG
---------------------------	---	--------	-----	-----------------------

TRI LO SPRINTEC				
-----------------	--	--	--	--

AB BARR	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N76784	001	Jun 29, 2009 Jun NEWA
---------	---	--------	-----	-----------------------

ETHINYLMESTRADIOL; NORGESTREL

TABLET; ORAL-21

OGESTREL 0.5/50-21				
--------------------	--	--	--	--

@ WATSON LABS	0.05MG;0.5MG	N75406	001	Dec 15, 1999 Apr DISC
---------------	--------------	--------	-----	-----------------------

TABLET; ORAL-21

OVRAL
@ AKRIMAX PHARMS 0.05MG;0.5MG N16672 001 Mar CAHN

ETHOTOIN

TABLET; ORAL
PEGANONE
+ LUNDBECK INC 250MG N10841 001 Apr CAHN
@ 500MG N10841 003 Apr CAHN

ETOPOSIDE

CAPSULE; ORAL
ETOPOSIDE
+ GENPHARM 50MG N75635 001 Sep 19, 2001 Feb CRLD
VEPESID
@ BRISTOL MYERS SQUIBB 50MG N19557 001 Dec 30, 1986 Feb DISC

EVEROLIMUS

TABLET; ORAL
AFINITOR
NOVARTIS 5MG N22334 001 Mar 30, 2009 Mar NEWA
+ 10MG N22334 002 Mar 30, 2009 Mar NEWA

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE
AB ALEMBIC LTD 20MG N78916 001 May 22, 2009 May NEWA
AB 40MG N78916 002 May 22, 2009 May NEWA
@ SANDOZ 20MG N75302 001 Apr 16, 2001 Mar DISC
@ 40MG N75302 002 Apr 16, 2001 Mar DISC

FEBUXOSTAT

TABLET; ORAL
ULORIC
TAKEDA PHARMS 40MG N21856 001 Feb 13, 2009 Feb NEWA
+ 80MG N21856 002 Feb 13, 2009 Feb NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL
>A> NALFON N17604 003 Jul CTNA
>A> + PEDINOL EQ 200MG BASE N17604 002 Feb DISC
@ EQ 300MG BASE
EQ 400MG BASE N17604 004 Jul 21, 2009 Jul NEWA
>D> NALFON 200 N17604 003 Jul CTNA
>D> + PEDINOL EQ 200MG BASE N17604 003 Feb CRLD
+ EQ 200MG BASE

TABLET; ORAL
FENOPROFEN CALCIUM
@ SANDOZ EQ 600MG BASE N72396 001 Oct 17, 1988 Mar DISC

FENTANYL CITRATE

>A> FILM; BUCCAL
>A> ONSOLIS
>A> BIODELIVERY SCI EQ 0.2MG BASE N22266 001 Jul 16, 2009 Jul NEWA
>A> EQ 0.4MG BASE N22266 002 Jul 16, 2009 Jul NEWA
>A> EQ 0.6MG BASE N22266 003 Jul 16, 2009 Jul NEWA

>A> FILM; Buccal
 >A> ONSOLIS
 >A> BIODELIVERY SCI EQ 0.8MG BASE N22266 004 Jul 16, 2009 Jul NEWA
 >A> EQ 1.2MG BASE N22266 005 Jul 16, 2009 Jul NEWA
 INJECTABLE; INJECTION
 SUBLIMAZE PRESERVATIVE FREE
 AP + AKORN EQ 0.05MG BASE/ML N16619 001 May CAHN

FERUMOXYTOL

SOLUTION; INTRAVENOUS
 FERAHEME
 + AMAG PHARMS INC EQ 510MG IRON/17ML (EQ 30MG IRON/ML) N22180 001 Jun 30, 2009 Jun NEWA

FLECAINIDE ACETATE

TABLET; ORAL
 FLECAINIDE ACETATE
 AB APOTEX INC 50MG N79164 001 Jul 09, 2009 Jun NEWA
 AB 100MG N79164 002 Jul 09, 2009 Jun NEWA
 AB 150MG N79164 003 Jul 09, 2009 Jun NEWA
 @ SANDOZ 50MG N76030 001 Oct 28, 2002 Mar DISC
 @ 100MG N76030 002 Oct 28, 2002 Mar DISC
 @ 150MG N76030 003 Oct 28, 2002 Mar DISC

FLUCONAZOLE

INJECTABLE; INJECTION
 FLUCONAZOLE
 >A> AP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) N79104 001 Jul 30, 2009 Jul NEWA
 >A> AP 400MG/200ML (2MG/ML) N79104 002 Jul 30, 2009 Jul NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
 FLUDARA
 AP + GENZYME 50MG/VIAL N20038 001 Apr 18, 1991 Jun CAHN
 FLUDARABINE PHOSPHATE
 AP ACTAVIS TOTOWA 50MG/VIAL N78610 001 Feb 11, 2009 Feb NEWA
 TABLET; ORAL
 >D> FLUDARABINE PHOSPHATE
 >D> + SANOFI AVENTIS US 10MG N22273 001 Dec 18, 2008 Jul CTNA
 + 10MG N22273 001 Dec 18, 2008 Jun CAHN
 >A> OFORTA
 >A> + SANOFI AVENTIS US 10MG N22273 001 Dec 18, 2008 Jul CTNA

FLUMAZENIL

INJECTABLE; INJECTION
 FLUMAZENIL
 AP HIKMA FARMACEUTICA 0.5MG/5ML (0.1MG/ML) N78527 001 Mar 23, 2009 Mar NEWA
 AP 1MG/10ML (0.1MG/ML) N78527 002 Mar 23, 2009 Mar NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
 DERMA-SMOOTH/FS
 + HILL DERMAC 0.01% N19452 002 Nov 09, 2005 Feb NEWA
 OIL/DROPS; OTIC
 >A> DERMOTIC
 >A> + HILL DERMAC 0.01% N19452 003 Nov 09, 2005 Jul CTNA

OIL/DROPS; OTIC

>D> FLUOCINOLONE ACETONIDE
 >D> + HILL DERMAC 0.01% N19452 003 Nov 09, 2005 Jul CTNA
 SHAMPOO; TOPICAL
 CAPEX
 + GALDERMA LABS LP 0.01% N20001 001 Aug 27, 1990 Jun CTNA

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE
 @ ALCON 0.1%;0.3% N50628 001 Jul 21, 1989 Jun DISC

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX
 @ ELORAC 1% N16765 001 Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC LTD	EQ 10MG BASE	N90223 001 Mar 19, 2009 Mar NEWA
AB1		EQ 20MG BASE	N90223 002 Mar 19, 2009 Mar NEWA
AB		EQ 40MG BASE	N90223 003 Mar 19, 2009 Mar NEWA
AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165 001 Feb 01, 2002 Mar CAHN
AB1		EQ 20MG BASE	N76165 002 Feb 01, 2002 Mar CAHN
>A>	AB1 LANDELA PHARM	EQ 10MG BASE	N75464 001 Jan 30, 2002 Jul CAHN
>A>	AB1	EQ 20MG BASE	N75464 002 Jan 30, 2002 Jul CAHN
>D>	AB1 RXELITE	EQ 10MG BASE	N75464 001 Jan 30, 2002 Jul CAHN
>D>	AB1	EQ 20MG BASE	N75464 002 Jan 30, 2002 Jul CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209 001 Mar 20, 2009 Mar NEWA
	PROZAC		
	@ LILLY	EQ 20MG BASE/5ML	N20101 001 Apr 24, 1991 Jun DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	MYLAN	EQ 10MG BASE	N75755 001 Aug 02, 2001 Apr CAHN
+		EQ 20MG BASE	N75755 002 Aug 02, 2001 Apr CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ SANDOZ	15MG	N71716 001 Jul 31, 1991 Mar DISC
@	30MG	N71717 001 Jul 31, 1991 Mar DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@ SANDOZ	50MG	N74448 001 Jul 28, 1995 Mar DISC
@	100MG	N74448 002 Jul 28, 1995 Mar DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ IVAX PHARMS	25MG	N75898 001 Mar 12, 2001 Mar DISC
@	50MG	N75898 002 Mar 12, 2001 Mar DISC

TABLET; ORAL

FLUVOXAMINE MALEATE
@ IVAX PHARMS

100MG

N75898 003 Mar 12, 2001 Mar DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID
AA INVAGEN PHARMS

1MG

N90035 001 Jun 09, 2009 Jun NEWA

FOMEPIZOLE

INJECTABLE; INJECTION
FOMEPIZOLE

AP GENERAMEDIX

1.5GM/1.5ML (1GM/ML)

N79033 001 Apr 07, 2009 Mar NEWA

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL
MONUROL

+ ZAMBON SPA

EQ 3GM BASE/PACKET

N50717 001 Dec 19, 1996 Jun CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ SANDOZ

10MG

N76188 001 Oct 08, 2004 Mar DISC

@

20MG

N76188 002 Oct 08, 2004 Mar DISC

@

40MG

N76188 003 Oct 08, 2004 Mar DISC

AB + TEVA

40MG

N76139 003 Nov 25, 2003 Jun CRLD

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB AUROBINDO PHARMA

10MG;12.5MG

N79245 001 Jul 09, 2009 Jun NEWA

AB @

20MG;12.5MG

N79245 002 Jul 09, 2009 Jun NEWA

AB INVAGEN PHARMS

10MG;12.5MG

N90228 001 Jul 09, 2009 Jun NEWA

AB 20MG;12.5MG

20MG;12.5MG

N90228 002 Jul 09, 2009 Jun NEWA

AB + TEVA

20MG;12.5MG

N76945 002 Jul 05, 2006 Jun CRLD

MONOPRIL-HCT

@ BRISTOL MYERS SQUIBB

10MG;12.5MG

N20286 002 Nov 30, 1994 Feb DISC

@

20MG;12.5MG

N20286 001 Nov 30, 1994 Feb DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>D> AP BAXTER HLTHCARE

10MG/ML

N71439 001 Sep 14, 1990 Jul DISC

>A> @

10MG/ML

N71439 001 Sep 14, 1990 Jul DISC

TABLET; ORAL

FUROSEMIDE

AB IPCA LABS LTD

20MG

N78010 001 Sep 18, 2006 Jun CAHN

AB 40MG

40MG

N78010 002 Sep 18, 2006 Jun CAHN

AB 80MG

80MG

N78010 003 Sep 18, 2006 Jun CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>D> AB SANDOZ

100MG

N75428 001 Jan 24, 2006 Jul DISC

>A> @

100MG

N75428 001 Jan 24, 2006 Jul DISC

>D> AB 300MG

300MG

N75428 002 Jan 24, 2006 Jul DISC

CAPSULE; ORAL

GABAPENTIN

>A>	@ SANDOZ	300MG	N75428 002	Jan 24, 2006	Jul	DISC
>D> AB		400MG	N75428 003	Jan 24, 2006	Jul	DISC
>A>	@	400MG	N75428 003	Jan 24, 2006	Jul	DISC

TABLET; ORAL

GABAPENTIN

>D> AB	RANBAXY	600MG	N76605 001	Sep 14, 2005	Jul	DISC
>A>	@	600MG	N76605 001	Sep 14, 2005	Jul	DISC
>D> AB		800MG	N76605 002	Sep 14, 2005	Jul	DISC
>A>	@	800MG	N76605 002	Sep 14, 2005	Jul	DISC
>D> AB	SANDOZ	600MG	N76120 001	Jan 27, 2006	Jul	DISC
>A>	@	600MG	N76120 001	Jan 27, 2006	Jul	DISC
>D> AB		800MG	N76120 002	Jan 27, 2006	Jul	DISC
>A>	@	800MG	N76120 002	Jan 27, 2006	Jul	DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	IMPAX LABS	EQ 8MG BASE	N78484 001	May 27, 2009	May	NEWA
AB		EQ 16MG BASE	N78484 002	May 27, 2009	May	NEWA
AB		EQ 24MG BASE	N78484 003	May 27, 2009	May	NEWA

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA	ROXANE	4MG/ML	N78185 001	Jan 30, 2009	Jan	NEWA
	RAZADYNE					
AA	+ ORTHO MCNEIL JANSSEN	4MG/ML	N21224 001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	BEIJING YABAO	EQ 4MG BASE	N77604 001	Feb 06, 2009	Apr	CAHN
AB		EQ 8MG BASE	N77604 002	Feb 06, 2009	Apr	CAHN
AB		EQ 12MG BASE	N77604 003	Feb 06, 2009	Apr	CAHN
AB	MYLAN	EQ 4MG BASE	N77590 001	May 29, 2009	May	NEWA
AB		EQ 4MG BASE	N77603 001	Aug 28, 2008	Apr	CAHN
AB		EQ 8MG BASE	N77590 002	May 29, 2009	May	NEWA
AB		EQ 8MG BASE	N77603 002	Aug 28, 2008	Apr	CAHN
AB		EQ 12MG BASE	N77590 003	May 29, 2009	May	NEWA
AB		EQ 12MG BASE	N77603 003	Aug 28, 2008	Apr	CAHN
AB	PAR PHARM	EQ 4MG BASE	N77604 001	Feb 06, 2009	Jan	NEWA
AB		EQ 8MG BASE	N77604 002	Feb 06, 2009	Jan	NEWA
AB		EQ 12MG BASE	N77604 003	Feb 06, 2009	Jan	NEWA
AB	ROXANE	EQ 4MG BASE	N77608 001	Feb 11, 2009	Jan	NEWA
AB		EQ 8MG BASE	N77608 002	Feb 11, 2009	Jan	NEWA
AB		EQ 12MG BASE	N77608 003	Feb 11, 2009	Jan	NEWA
AB	SANDOZ	EQ 4MG BASE	N77589 001	Jun 22, 2009	Jun	NEWA
AB		EQ 8MG BASE	N77589 002	Jun 22, 2009	Jun	NEWA
AB		EQ 12MG BASE	N77589 003	Jun 22, 2009	Jun	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	N77587 001	Jul 09, 2009	Jun	NEWA
AB		EQ 8MG BASE	N77587 002	Jul 09, 2009	Jun	NEWA
AB		EQ 12MG BASE	N77587 003	Jul 09, 2009	Jun	NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

@ ROCHE PALO

EQ 500MG BASE/VIAL

N19661 001 Jun 23, 1989 Jun DISC

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

+ BEDFORD

EQ 500MG BASE/VIAL

N76222 001 Jul 16, 2003 Jun CRLD

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

>D>	RANBAXY	3MG	N77366 001 Oct 06, 2005 Jul DISC
>A>	@	3MG	N77366 001 Oct 06, 2005 Jul DISC
>D>		6MG	N77366 002 Oct 06, 2005 Jul DISC
>A>	@	6MG	N77366 002 Oct 06, 2005 Jul DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+ TAKEDA GLOBAL

2MG;30MG

N21925 001 Jul 28, 2006 May CRLD

4MG;30MG

N21925 002 Jul 28, 2006 May CRLD

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	+ TEVA	5MG	N74388 003 Aug 29, 1995 Mar CRLD
	MICRONASE		
	@ PHARMACIA AND UPJOHN	1.25MG	N17498 001 May 01, 1984 Mar DISC
	@	2.5MG	N17498 002 May 01, 1984 Mar DISC
	@	5MG	N17498 003 May 01, 1984 Mar DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	+ BRISTOL MYERS SQUIBB	2.5MG;500MG	N21178 002 Jul 31, 2000 May CRLD
AB		5MG;500MG	N21178 003 Jul 31, 2000 May CRLD
	GLYBURIDE AND METFORMIN HYDROCHLORIDE		
AB	DR REDDYS LABS INC	1.25MG;250MG	N79009 001 Jun 03, 2009 May NEWA
AB		2.5MG;500MG	N79009 002 Jun 03, 2009 May NEWA
AB		5MG;500MG	N79009 003 Jun 03, 2009 May NEWA

GLCOPYRROLATE

TABLET; ORAL

GLCOPYRROLATE

AA	WEST WARD	1MG	N40836 001 Mar 05, 2009 Feb NEWA
AA		2MG	N40836 002 Mar 05, 2009 Feb NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78534 001 Apr 30, 2009 Apr NEWA
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N78531 001 Apr 30, 2009 Apr NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N78531 002 Apr 30, 2009 Apr NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB	DR REDDYS LABS LTD	EQ 1MG BASE	N78846 001 Feb 27, 2009 Feb NEWA
AB	NATCO PHARMA	EQ 1MG BASE	N78969 001 Jun 22, 2009 Jun NEWA

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	MYLAN	10MG	N70278 002 Jul 16, 2009 Jun NEWA
AB		20MG	N70278 003 Jul 16, 2009 Jun NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

@ SANDOZ	EQ 50MG BASE/ML	N76463 001 Jun 24, 2005 Apr DISC
@	EQ 100MG BASE/ML	N76463 002 Jun 24, 2005 Apr DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

@ SANDOZ	EQ 5MG BASE/ML	N76464 001 Sep 29, 2004 Apr DISC
----------	----------------	----------------------------------

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
SUPPRELIN LA

+ ENDO PHARM	50MG	N22058 001 May 03, 2007 Apr CAHN
VANTAS		
+ ENDO PHARM	50MG	N21732 001 Oct 12, 2004 Apr CAHN
+ ENDO PHARMS	50MG	N21732 001 Oct 12, 2004 Mar CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYCODAN

@ ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002 Jul 26, 1988 Feb DISC
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE		
AA + HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613 001 Feb 08, 2008 Feb CRLD

TABLET; ORAL
HYCODAN

@ ENDO PHARMS	1.5MG;5MG	N05213 001 Jul 26, 1988 Feb DISC
---------------	-----------	----------------------------------

AA + KING PHARMS

TUSSIGON		
	1.5MG;5MG	N88508 001 Jul 30, 1985 Feb CRLD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP AKORN	20MG/ML	N40730 001 Apr 21, 2009 Mar NEWA
----------	---------	----------------------------------

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

AA GLENMARK PHARMS LTD	10MG	N90527 001 May 27, 2009 May NEWA
AA	25MG	N90527 002 May 27, 2009 May NEWA
AA	50MG	N90527 003 May 27, 2009 May NEWA
AA	100MG	N90527 004 May 27, 2009 May NEWA
@ SANDOZ	10MG	N83241 001 Mar DISC
@	25MG	N83560 001 Mar DISC
@	50MG	N83561 001 Mar DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB IPCA LABS LTD	12.5MG	N79237 001 Apr 02, 2009 Mar NEWA
------------------	--------	----------------------------------

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE
AB ROXANE 4MG

N74597 003 May 29, 2009 May NEWA

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB BARR 500MG N75143 001 Oct 16, 1998 Feb CMFD

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HYDROCHLORIDE

AP + ABRAXIS PHARM 25MG/ML N87329 001 Jun CRLD

AP + 50MG/ML N87329 002 Jun CRLD

VISTARIL

@ PFIZER 25MG/ML N11111 001 Jun DISC
@ 50MG/ML N11111 002 Jun DISC

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ SANDOZ 10MG N87869 001 Dec 20, 1982 Mar DISC

@ 25MG N87870 001 Dec 20, 1982 Mar DISC

@ 50MG N87871 001 Dec 20, 1982 Mar DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ SANDOZ EQ 25MG HCL N81127 001 Jun 28, 1991 Mar DISC

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

>D> + ROCHE EQ 2.5MG BASE N21455 001 May 16, 2003 Jul DISC

>A> @ EQ 2.5MG BASE N21455 001 May 16, 2003 Jul DISC

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS 400MG/4ML (100MG/ML) N22348 001 Jun 11, 2009 Jun NEWA

+ 800MG/8ML (100MG/ML) N22348 002 Jun 11, 2009 Jun NEWA

TABLET; ORAL

IBUPROFEN

AB + DR REDDYS LA 800MG N75682 003 Nov 14, 2001 Feb CRLD

@ SANDOZ 300MG N70734 001 Jun 12, 1986 Mar DISC

@ 400MG N70735 001 Jun 12, 1986 Mar DISC

@ 600MG N70736 001 Jun 12, 1986 Mar DISC

@ 800MG N72169 001 Dec 11, 1987 Mar DISC

AB SHASUN USA 400MG N78329 001 Feb 05, 2009 Jan NEWA

AB 600MG N78329 002 Feb 05, 2009 Jan NEWA

AB 800MG N78329 003 Feb 05, 2009 Jan NEWA

MOTRIN

@ MCNEIL CONSUMER 300MG N17463 003 Apr DISC

@ 400MG N17463 002 Feb DISC

@ 600MG N17463 004 Feb DISC

@ 800MG N17463 005 May 22, 1985 Feb DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS
 NEOPROFEN
 + LUNDBECK INC EQ 20MG BASE/2ML (EQ 10MG
 BASE/ML) N21903 001 Apr 13, 2006 Apr CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
 IDARUBICIN HYDROCHLORIDE
 >A> AP APP PHARMS 1MG/ML N65440 001 Aug 04, 2009 Jul NEWA

IFOSFAMIDE

INJECTABLE; INJECTION
 IFEX
 @ BAXTER HLTHCARE 1GM/VIAL N19763 001 Dec 30, 1988 Feb CAHN
 @ 3GM/VIAL N19763 002 Dec 30, 1988 Feb CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
 IFEX/MESNEX KIT
 + BAXTER HLTHCARE 1GM/VIAL;100MG/ML N19763 003 Oct 10, 1992 Feb CAHN
 + 3GM/VIAL;100MG/ML N19763 004 Oct 10, 1992 Feb CAHN

ILOPERIDONE

TABLET; ORAL
 FANAPT
 VANDA PHARMS INC 1MG N22192 001 May 06, 2009 May NEWA
 2MG N22192 002 May 06, 2009 May NEWA
 4MG N22192 003 May 06, 2009 May NEWA
 6MG N22192 004 May 06, 2009 May NEWA
 8MG N22192 005 May 06, 2009 May NEWA
 10MG N22192 006 May 06, 2009 May NEWA
 + 12MG N22192 007 May 06, 2009 May NEWA

INDINAVIR SULFATE

CAPSULE; ORAL
 CRIXIVAN
 @ MERCK EQ 333MG BASE N20685 005 Dec 17, 1998 Jun DISC

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
 INDOVIN SR
 AB + SANDOZ 75MG N74464 001 May 28, 1998 Feb CTEC
 INDOMETHACIN
 AB AVANTHI INC 75MG N79175 001 Mar 06, 2009 Feb NEWA
 SUSPENSION; ORAL
 INDOVIN
 + IROKO PHARMS 25MG/5ML N18332 001 Oct 10, 1985 Mar CAHN

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
 INDOVIN
 AP + LUNDBECK INC EQ 1MG BASE/VIAL N18878 001 Jan 30, 1985 Apr CAHN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 APIDRA SOLOSTAR
 SANOFI AVENTIS US 300 UNITS/3ML

N21629 003 Feb 24, 2009 Feb NEWA

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION
 EXUBERA
 @ PFIZER 1MG/INH
 @ 3MG/INH

N21868 001 Jan 27, 2006 Jun DISC
 N21868 002 Jan 27, 2006 Jun DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
 IPRATROPIUM BROMIDE
 AN TEVA PARENTERAL 0.02%

N75313 001 Feb 07, 2000 Apr CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
 IRINOTECAN HYDROCHLORIDE
 AP PHARMAFORCE 40MG/2ML (20MG/ML)
 AP 40MG/2ML(20MG/ML)
 AP 100MG/5ML (20MG/ML)
 AP 100MG/5ML(20MG/ML)

N90016 001 Jan 28, 2009 Mar NEWA
 N90016 001 Jan 28, 2009 Jan NEWA
 N90016 002 Jan 28, 2009 Mar NEWA
 N90016 002 Jan 28, 2009 Jan NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
 ISOSORBIDE DINITRATE
 @ SANDOZ 2.5MG
 @ 5MG

N86225 001 Feb 19, 1988 Mar DISC
 N86222 001 Feb 19, 1988 Mar DISC

ISOTRETINOIN

CAPSULE; ORAL
 ACCUTANE
 >D> AB HLR 10MG
 >D> AB + 20MG
 >D> AB + 40MG
 >A> HOFFMANN LA ROCHE 10MG
 >A> @ 20MG
 >A> @ 40MG

N18662 002 May 07, 1982 Jul DISC
 N18662 004 Mar 28, 1983 Jul DISC
 N18662 003 May 07, 1982 Jul DISC
 N18662 002 May 07, 1982 Jul DISC
 N18662 004 Mar 28, 1983 Jul DISC
 N18662 003 May 07, 1982 Jul DISC

KETOCONAZOLE

GEL; TOPICAL
 XOLEGEL
 + STIEFEL LABS INC 2%

N21946 001 Jul 28, 2006 Jan CAHN

KETOPROFEN

CAPSULE; ORAL
 KETOPROFEN
 @ SANDOZ 50MG
 @ 75MG

N74024 001 Dec 29, 1995 Mar DISC
 N74024 002 Dec 29, 1995 Mar DISC

KETOROLAC TROMETHAMINE

>A>	SOLUTION/DROPS; OPHTHALMIC						
>A>	ACUVAIL						
>A>	+ ALLERGAN	0.45%				N22427 001	Jul 22, 2009 Jul NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	APOTEX INC	25MG	N78625 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625 004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956 004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132 004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N76708 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708 004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428 004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443 001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443 002	Feb 11, 2009	Jan	NEWA
AB		150MG	N78443 003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443 004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77420 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420 004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392 004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645 004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525 004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947 004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310 001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310 002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310 003	Feb 04, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	UPSHER SMITH	200MG	N78310 004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982 004	Jan 27, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA	25MG	N77633 001	Jan 27, 2009	Jan	NEWA
		50MG	N77633 002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633 003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633 004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633 005	Jan 27, 2009	Jan	NEWA
		250MG	N77633 006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099 001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099 002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204 001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204 002	Feb 04, 2009	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

SMITHKLINE BEECHAM	25MG	N22115 001	May 29, 2009	May	NEWA
	50MG	N22115 002	May 29, 2009	Jul	CRLD
>D>		N22115 002	May 29, 2009	Jul	CRLD
>A>	+	N22115 002	May 29, 2009	May	NEWA
		N22115 002	May 29, 2009	May	NEWA
	50MG	N22115 003	May 29, 2009	May	NEWA
		N22115 003	May 29, 2009	May	NEWA
>D>	+	N22115 004	May 29, 2009	Jul	CRLD
>A>		N22115 004	May 29, 2009	Jul	CRLD
		N22115 004	May 29, 2009	May	NEWA
	200MG	N22115 004	May 29, 2009	May	NEWA
		N22115 004	May 29, 2009	May	NEWA
	200MG	N22115 004	May 29, 2009	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

SMITHKLINE BEECHAM	25MG	N22251 001	May 08, 2009	May	NEWA
	50MG	N22251 002	May 08, 2009	Jul	CRLD
>D>		N22251 002	May 08, 2009	Jul	CRLD
>A>	+	N22251 002	May 08, 2009	May	NEWA
		N22251 002	May 08, 2009	May	NEWA
	50MG	N22251 003	May 08, 2009	May	NEWA
		N22251 003	May 08, 2009	May	NEWA
	100MG	N22251 004	May 08, 2009	Jul	CRLD
>D>	+	N22251 004	May 08, 2009	Jul	CRLD
>A>		N22251 004	May 08, 2009	Jul	CRLD
		N22251 004	May 08, 2009	May	NEWA
	200MG	N22251 004	May 08, 2009	May	NEWA
		N22251 004	May 08, 2009	May	NEWA
	200MG	N22251 004	May 08, 2009	May	NEWA

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

@ TAKEDA PHARMS NA	15MG/PACKET	N21281 001	May 03, 2001	May	DISC
@	30MG/PACKET	N21281 002	May 03, 2001	May	DISC

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

@ COREPHARMA	EQ 5MG BASE	N74544 001	Aug 28, 1997	Jun	CAHN
@	EQ 25MG BASE	N74544 002	Aug 28, 1997	Jun	CAHN
	EQ 10MG BASE	N72734 001	Feb 22, 1993	Jun	CTEC
ROXANE	EQ 5MG BASE	N18459 001	Jan 30, 1986	May	DISC
@ XANODYNE PHARM	EQ 10MG BASE	N71962 001	Nov 19, 1987	Jun	DISC
@	EQ 10MG BASE				

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
 VIADUR
 @ ORTHO MCNEIL JANSSEN EQ 65MG BASE N21088 001 Mar 03, 2000 Jun DISC

INJECTABLE; INJECTION
 LEUPROLIDE ACETATE
 AP SUN PHARMA GLOBAL 1MG/0.2ML N78885 001 Mar 09, 2009 Feb NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
 LEVALBUTEROL HYDROCHLORIDE
 AN DEY EQ 0.25% BASE N78309 001 Mar 20, 2009 Mar NEWA
 XOPENEX
 AN + SEPRACOR EQ 0.25% BASE N20837 004 Jul 18, 2003 Mar CFTG

LEVETIRACETAM

SOLUTION; ORAL
 LEVETIRACETAM
 AA SILARX 100MG/ML N90263 001 Apr 03, 2009 Mar NEWA
 AA TARO 100MG/ML N78774 001 Feb 10, 2009 Jan NEWA

TABLET; ORAL
 LEVETIRACETAM
 AB APOTEX INC 250MG N78869 001 Mar 13, 2009 Mar NEWA
 AB 500MG N78869 002 Mar 13, 2009 Mar NEWA
 AB 750MG N78869 003 Mar 13, 2009 Mar NEWA
 AB 1GM N78869 004 Mar 13, 2009 Mar NEWA
 AB CIPLA LTD 250MG N77319 001 Mar 20, 2009 Mar NEWA
 AB 500MG N77319 002 Mar 20, 2009 Mar NEWA
 AB 750MG N77319 003 Mar 20, 2009 Mar NEWA
 AB GENPHARM ULC 250MG N78731 001 Feb 10, 2009 Jan NEWA
 AB 500MG N78731 002 Feb 10, 2009 Jan NEWA
 AB 750MG N78731 003 Feb 10, 2009 Jan NEWA
 AB 1GM N78731 004 Feb 10, 2009 Jan NEWA
 AB SOLCO HLTHCARE 250MG N78106 001 Feb 10, 2009 Jan NEWA
 AB 500MG N78106 002 Feb 10, 2009 Jan NEWA
 AB 750MG N78106 003 Feb 10, 2009 Jan NEWA
 AB 1GM N78106 004 Feb 10, 2009 Jan NEWA
 AB WATSON LABS FLORIDA 250MG N77408 001 Mar 02, 2009 Feb NEWA
 AB 500MG N77408 002 Mar 02, 2009 Feb NEWA
 AB 750MG N77408 003 Mar 02, 2009 Feb NEWA
 AB ZYDUS PHARMS USA INC 250MG N78918 001 Apr 29, 2009 Apr NEWA
 AB 1GM N78918 002 Apr 29, 2009 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL
 KEPPIRA XR
 UCB INC 500MG N22285 001 Sep 12, 2008 Feb CRLD
 + 750MG N22285 002 Feb 12, 2009 Feb NEWA

LEVOFLOXACIN

TABLET; ORAL
 LEVAQUIN
 ORTHO MCNEIL JANSSEN 250MG N20634 001 Dec 20, 1996 Jun CTEC
 AB 250MG N20634 001 Dec 20, 1996 Apr CFTG
 AB 500MG N20634 002 Dec 20, 1996 Jun CTEC
 AB 500MG N20634 002 Dec 20, 1996 Apr CFTG
 + 750MG N20634 003 Sep 08, 2000 Jun CTEC

TABLET; ORAL

LEVAQUIN

AB + ORTHO MCNEIL JANSSEN 750MG N20634 003 Sep 08, 2000 Apr CFTG

LEVONORGESTREL

>D>	IMPLANT; IMPLANTATION					
>D>	NORPLANT II					
>D>	+ POPULATION COUNCIL	75MG/IMPLANT				N20544 001 Nov 01, 1996 Jul DISC
>A>	@	75MG/IMPLANT				N20544 001 Nov 01, 1996 Jul DISC
TABLET; ORAL						
LEVONORGESTREL						
AB	WATSON LABS	0.75MG				N78666 001 Jun 24, 2009 Jun NEWA
>A>	PLAN B ONE-STEP					
>A>	+ DURAMED	1.5MG				N21998 001 Jul 10, 2009 Jul NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2,	MERCK KGAA	0.025MG				N76752 001 Jun 16, 2005 Apr CAHN
AB3		0.05MG				N76752 002 Jun 16, 2005 Apr CAHN
AB2,		0.075MG				N76752 003 Jun 16, 2005 Apr CAHN
AB3		0.088MG				N76752 004 Jun 16, 2005 Apr CAHN
AB2,		0.1MG				N76752 005 Jun 16, 2005 Apr CAHN
AB3		0.112MG				N76752 006 Jun 16, 2005 Apr CAHN
AB2,		0.125MG				N76752 007 Jun 16, 2005 Apr CAHN
AB3		0.15MG				N76752 008 Jun 16, 2005 Apr CAHN
AB2,		0.175MG				N76752 009 Jun 16, 2005 Apr CAHN
AB3		0.2MG				N76752 010 Jun 16, 2005 Apr CAHN
AB2,		0.3MG				N76752 011 Jun 16, 2005 Apr CAHN
AB3						

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

@ HOSPIRA 10%

N88367 001 Jul 31, 1984 Apr DISC

XYLOCAINE

AP	+ APP PHARMS	2%				N06488 002 Apr CMFD
XYLOCAINE DENTAL						
AP	+ DENTSPLY PHARM	2%				N21380 001 Apr CTNA
SYSTEM; INTRADERMAL						
ZINGO						
@ ANESIVA 0.5MG N22114 001 Aug 16, 2007 May DISC						

LINDANE

LOTION; TOPICAL

LINDANE

@ OLTA PHARMS 1%

N87313 001 Apr CAHN

SHAMPOO; TOPICAL

LINDANE

AT + OLTA PHARMS 1% N87266 001 Jan CAHN

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB KING PHARMS	EQ 0.005MG BASE	N10379 001	Mar	CFTG
AB	EQ 0.025MG BASE	N10379 002	Mar	CTEC
AB +	EQ 0.05MG BASE	N10379 003	Mar	CTEC
LIOTHYRONINE SODIUM				
AB COASTAL PHARMS	EQ 0.005MG BASE	N90097 001	Mar 20,	2009 Mar NEWA
AB	EQ 0.025MG BASE	N90097 002	Mar 20,	2009 Mar NEWA
AB	EQ 0.05MG BASE	N90097 003	Mar 20,	2009 Mar NEWA
AB MYLAN	EQ 0.005MG BASE	N90326 001	Jul 14,	2009 Jun NEWA
AB	EQ 0.025MG BASE	N90326 002	Jul 14,	2009 Jun NEWA
AB	EQ 0.05MG BASE	N90326 003	Jul 14,	2009 Jun NEWA

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB GLENMARK GENERICS	150MG	N79139 001	Feb 03,	2009 Jan NEWA
AB	300MG	N79139 002	Feb 03,	2009 Jan NEWA
AB	600MG	N79139 003	Feb 03,	2009 Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

@ SANDOZ 2MG N72993 001 Aug 28, 1992 Mar DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA PADDOCK LABS	2MG/ML	N79244 001	Apr 28,	2009 Apr NEWA
AA + ROXANE	2MG/ML	N72755 001	Jun 28,	1991 Apr CFTG
SOLUTION; ORAL				
LORAZEPAM				
@ ROXANE	0.5MG/5ML	N74648 001	Mar 18,	1997 Mar DISC

MALATHION

LOTION; TOPICAL

MALATHION

AT SYNERX PHARMA	0.5%	N78743 001	Mar 06,	2009 Feb NEWA
OVIDE				
AT + TARO PHARMS NORTH	0.5%	N18613 001	Aug 02,	1982 Feb CFTG

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUSTARGEN

+ LUNDBECK INC 10MG/VIAL N06695 001 Apr CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA + PFIZER 12.5MG N10721 006 Jan CAHN

TABLET; ORAL

ANTIVERT

AA +	PFIZER	25MG	N10721 004	Jan	CAHN
AA +		50MG	N10721 001	Jan 20, 1982	Jan CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ SANDOZ	EQ 50MG BASE	N72262 001	Nov 29, 1988	Mar	DISC
@	EQ 100MG BASE	N72263 001	Nov 29, 1988	Mar	DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB	SANDOZ	150MG/ML	N78711 001	May 20, 2009	May NEWA
----	--------	----------	------------	--------------	----------

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	BEIJING YABAO	7.5MG	N77933 001	Jul 19, 2006	Apr	CAHN
AB		15MG	N77933 002	Jul 19, 2006	Apr	CAHN
AB	STRIDES ARCOLAB LTD	7.5MG	N77928 001	May 13, 2009	May	NEWA
AB		15MG	N77928 002	May 13, 2009	May	NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP +	GLAXOSMITHKLINE	EQ 50MG BASE/VIAL	N20207 001	Nov 18, 1992	Jun	CFTG
	MELPHALAN HYDROCHLORIDE					
AP	SYNERX	EQ 50MG BASE/VIAL	N90270 001	Jun 09, 2009	Jun	NEWA

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA	MIKART	50MG	N40893 001	Jun 24, 2009	Jun	NEWA
		75MG	N40893 002	Jun 24, 2009	Jun	NEWA
AA		100MG	N40893 003	Jun 24, 2009	Jun	NEWA
		150MG	N40893 004	Jun 24, 2009	Jun	NEWA

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

AP	APP PHARMS	1%	N89407 001	Dec 01, 1986	Jun	CAHN
AP		2%	N89410 001	Dec 01, 1986	Jun	CAHN
	POLOCAINE-MPF					
AP	APP PHARMS	1%	N89406 001	Dec 01, 1986	Jun	CAHN
AP		1.5%	N89408 001	Dec 01, 1986	Jun	CAHN
AP		2%	N89409 001	Dec 01, 1986	Jun	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	ALEMBIC LTD	200MG	N90122 001	Feb 18, 2009	Feb	NEWA
AA		400MG	N90122 002	Feb 18, 2009	Feb	NEWA
	@ IVC INDs	400MG	N84153 001		Apr	CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
 SOLAGE
 + STIEFEL LABS INC 2%;0.01% N20922 001 Dec 10, 1999 Jan CAHN

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
 >D> ASACOL
 >D> + PROCTER AND GAMBLE 800MG N21830 001 May 29, 2008 Jul CTNA
 + 800MG N21830 001 May 29, 2008 May CTNA
 >A> ASACOL HD
 >A> + PROCTER AND GAMBLE 800MG N21830 001 May 29, 2008 Jul CTNA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
 NORETHIN 1/50M-21
 @ WATSON LABS 0.05MG;1MG N71539 001 Apr 12, 1988 Apr DISC
 NORETHINDRONE AND MESTRANOL
 @ WATSON LABS 0.05MG;1MG N70758 001 Jul 01, 1988 Apr DISC
 NORINYL 1+50 21-DAY
 @ WATSON LABS 0.05MG;1MG N13625 002 Apr DISC
 TABLET; ORAL-28
 NORETHIN 1/50M-28
 @ WATSON LABS 0.05MG;1MG N71540 001 Apr 12, 1988 Apr DISC
 NORETHINDRONE AND MESTRANOL
 @ WATSON LABS 0.05MG;1MG N70759 001 Jul 01, 1988 Apr DISC
 NORINYL 1+50 28-DAY
 + WATSON LABS 0.05MG;1MG N16659 001 Apr CRLD
 ORTHO-NOVUM 1/50 28
 @ ORTHO MCNEIL JANSSEN 0.05MG;1MG N16709 001 Apr DISC

METAPROTERENOL SULFATE

SOLUTION; INHALATION
 ALUPENT
 @ BOEHRINGER INGELHEIM 0.4% N18761 002 Oct 10, 1986 Feb DISC
 @ 0.6% N18761 001 Jun 30, 1983 Feb DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL
 METFORMIN HYDROCHLORIDE
 AB ALVOGEN 500MG N76033 001 Jan 24, 2002 Jan CAHN
 AB 850MG N76033 002 Jan 24, 2002 Jan CAHN
 AB 1GM N76033 003 Jan 24, 2002 Jan CAHN
 AB PROVIDENT PHARM 500MG N77853 001 Jul 28, 2006 Apr CAHN
 AB 850MG N77853 002 Jul 28, 2006 Apr CAHN
 AB 1GM N77853 003 Jul 28, 2006 Apr CAHN
 TABLET, EXTENDED RELEASE; ORAL
 METFORMIN HYDROCHLORIDE
 @ SANDOZ 500MG N76223 001 Dec 14, 2004 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 ACTOPLUS MET XR
 TAKEDA GLOBAL 1GM;EQ 15MG BASE N22024 001 May 12, 2009 May NEWA
 + 1GM;EQ 30MG BASE N22024 002 May 12, 2009 May NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL				
DESOXYN				
+ LUNDBECK INC	5MG	N05378 002	Apr	CAHN
TABLET, EXTENDED RELEASE; ORAL				
DESOXYN				
@ LUNDBECK INC	5MG	N05378 004	Apr	CAHN
@	10MG	N05378 003	Apr	CAHN
@	15MG	N05378 005	Apr	CAHN

METHIMAZOLE

TABLET; ORAL				
METHIMAZOLE				
AB GENPHARM	10MG	N40350 002 Mar 29, 2000 May	CRLD	

METHOCARBAMOL

TABLET; ORAL				
METHOCARBAMOL				
@ SOLCO HLTHCARE	500MG	N86989 001	Jan	CAHN
@	750MG	N86988 001	Jan	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION				
METHOTREXATE SODIUM PRESERVATIVE FREE				
AP EBEWE PARENTA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	N90039 001 Mar 31, 2009 Mar	NEWA	
AP	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039 002 Mar 31, 2009 Mar	NEWA	
AP	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029 001 Mar 31, 2009 Mar	NEWA	

METHYCLOTHIAZIDE

TABLET; ORAL				
ENDURON				
ABBOTT	2.5MG	N12524 001	Mar	CTEC
METHYCLOTHIAZIDE				
@ SANDOZ	2.5MG	N89835 001 Aug 18, 1988 Mar	DISC	
@	5MG	N89837 001 Aug 18, 1988 Mar	DISC	

METHYLDOPA

TABLET; ORAL				
METHYLDOPA				
@ SANDOZ	125MG	N71700 001 Mar 02, 1988 Mar	DISC	
@	250MG	N18934 001 Jun 29, 1984 Mar	DISC	
@	500MG	N18934 002 Jun 29, 1984 Mar	DISC	

METHYLPREDNISOLONE

TABLET; ORAL				
MEDROL				
@ PHARMACIA AND UPJOHN	24MG	N11153 005	Jun	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION				
METHYLPREDNISOLONE ACETATE				
AB SANDOZ	40MG/ML	N40719 001 Jan 29, 2009 Jan	NEWA	
AB	40MG/ML	N40794 001 Mar 05, 2009 Feb	NEWA	

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ	80MG/ML	N40719 002 Jan 29, 2009 Jan NEWA
AB		80MG/ML	N40794 002 Mar 05, 2009 Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051 001 Jan 26, 2001 Mar CMFD
TABLET; ORAL			
METOCLOPRAMIDE HYDROCHLORIDE			
@	SANDOZ	EQ 5MG BASE	N74478 001 Oct 05, 1995 Mar DISC
@		EQ 10MG BASE	N72215 001 Jan 30, 1990 Mar DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>A>	AB	WATSON LABS FLORIDA	EQ 25MG TARTRATE	N77118 001 Aug 03, 2009 Jul NEWA
>A>	AB		EQ 50MG TARTRATE	N76862 001 Aug 03, 2009 Jul NEWA

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	MUTUAL PHARM	25MG	N73654 002 Jul 15, 2009 Jun NEWA
@	SOLCO HLTHCARE	50MG	N74453 001 Apr 27, 1995 Jan CAHN
@		100MG	N74453 002 Apr 27, 1995 Jan CAHN

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB	ALEMBIC LTD	375MG	N79065 001 Jun 23, 2009 Jun NEWA
TABLET; ORAL			
METRONIDAZOLE			
AB	ALEMBIC LTD	250MG	N79067 001 Mar 13, 2009 Mar NEWA
AB		500MG	N79067 002 Mar 13, 2009 Mar NEWA
@	SANDOZ	250MG	N18740 001 Oct 22, 1982 Mar DISC
@		500MG	N18740 002 Oct 22, 1982 Mar DISC
AB	WATSON LABS	250MG	N70035 001 Dec 20, 1984 Jun CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

@	SANDOZ	150MG	N74450 001 May 16, 1996 Mar DISC
@		200MG	N74450 002 May 16, 1996 Mar DISC
@		250MG	N74450 003 May 16, 1996 Mar DISC

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

@	ORTHONEUTROGENA	2%	N17494 001	Jun DISC
---	-----------------	----	------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	STIEFEL LABS INC	0.25%;81.35%;15%	N21026 001 Feb 16, 2006 Jan CAHN
---	------------------	------------------	----------------------------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

CYPRESS BIOSCIENCE	12.5MG	N22256 001	Jan 14, 2009	Jan	NEWA
	25MG	N22256 002	Jan 14, 2009	Jan	NEWA
	50MG	N22256 003	Jan 14, 2009	Jan	NEWA
+	100MG	N22256 004	Jan 14, 2009	Jan	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	+	BEDFORD	EQ 1MG BASE/ML	N75660 001	May 28, 2002	Jun	CRLD
----	---	---------	----------------	------------	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

+	TRIAZ PHARMS LLC	EQ 100MG BASE/VIAL	N50444 001	May	CMFD
---	------------------	--------------------	------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BARR	EQ 45MG BASE	N65485 001	Mar 17, 2009	Mar	NEWA
AB		EQ 90MG BASE	N65485 002	Mar 17, 2009	Mar	NEWA
AB		EQ 135MG BASE	N65485 003	Mar 17, 2009	Mar	NEWA
AB	IMPAX LABS INC	EQ 45MG BASE	N90024 001	Feb 03, 2009	Jan	NEWA
AB		EQ 90MG BASE	N90024 002	Feb 03, 2009	Jan	NEWA
AB		EQ 135MG BASE	N90024 003	Feb 03, 2009	Jan	NEWA
	SOLODYNE					
AB	MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	Jan	CFTG
>A>		EQ 65MG BASE	N50808 004	Jul 23, 2009	Jul	NEWA
>A>	AB	EQ 90MG BASE	N50808 002	May 08, 2006	Jan	CFTG
>A>		EQ 115MG BASE	N50808 005	Jul 23, 2009	Jul	NEWA
AB	+	EQ 135MG BASE	N50808 003	May 08, 2006	Jan	CFTG

MITOMYCIN

INJECTABLE; INJECTION

MUTAMYCIN

>D>	+	BRISTOL MYERS	40MG/VIAL	N62336 003	Mar 10, 1988	Jul	CTEC
>A>	AP	+	40MG/VIAL	N62336 003	Mar 10, 1988	Jul	CTEC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980 001	Apr 13, 2009	Mar	NEWA
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980 002	Apr 13, 2009	Mar	NEWA

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

+	EWEWE PARENTA	EQ 2MG BASE/ML	N78562 001	Apr 30, 2009	Apr	NEWA
---	---------------	----------------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+	ACTAVIS ELIZABETH	10MG	N20616 008	Apr 20, 2007	Feb	CRLD
---	-------------------	------	------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+ ACTAVIS ELIZABETH 80MG

N20616 006 Oct 27, 2006 Feb CRLD

INJECTABLE; INJECTION

ASTRAMORPH PF

AP APP PHARMS 0.5MG/ML

N71050 001 Oct 07, 1986 Jun CAHN

AP 0.5MG/ML

N71051 001 Oct 07, 1986 Jun CAHN

AP 1MG/ML

N71052 001 Oct 07, 1986 Jun CAHN

AP 1MG/ML

N71053 001 Oct 07, 1986 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ AB GENERICS 15MG

N74862 001 Jul 07, 1998 Apr DISC

@ 30MG

N74862 002 Jul 07, 1998 Apr DISC

@ 60MG

N74862 003 Jul 07, 1998 Apr DISC

@ 100MG

N74769 001 Jul 02, 1998 Apr DISC

@ 200MG

N74769 002 Jul 02, 1998 Apr DISC

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 160MG/100ML

N21277 001 Nov 30, 2001 Jun CAHN

TABLET; ORAL

AVELOX

+ BAYER HLTHCARE EQ 400MG BASE

N21085 001 Dec 10, 1999 Jun CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB ACCORD HLTHCARE INC 250MG

N90253 001 May 04, 2009 Apr NEWA

AB APOTEX CORP 250MG

N90419 001 Apr 22, 2009 Apr NEWA

AB MYLAN 250MG

N65520 001 May 04, 2009 Apr NEWA

AB TEVA PHARMS 250MG

N65491 001 May 06, 2009 Apr NEWA

AB ZYDUS PHARMS USA INC 250MG

N65433 001 May 04, 2009 Apr NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB ACCORD HLTHCARE 500MG

N65416 001 May 04, 2009 Apr NEWA

AB APOTEX 500MG

N90499 001 Apr 22, 2009 Apr NEWA

AB MYLAN 500MG

N65521 001 May 04, 2009 Apr NEWA

AB TEVA PHARMS 500MG

N65457 001 May 04, 2009 Apr NEWA

AB ZYDUS PHARMS USA INC 500MG

N65477 001 May 04, 2009 Apr NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB ACTAVIS ELIZABETH 500MG

N79093 001 Feb 27, 2009 Feb NEWA

AB 750MG

N79093 002 Feb 27, 2009 Feb NEWA

@ SANDOZ 500MG

N75590 001 Feb 25, 2002 Mar DISC

@ 750MG

N75590 002 Feb 25, 2002 Mar DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

MALLINCKRODT 100MG

N76264 003 Mar 22, 2002 May CRLD

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL
NAPRELAN

+ STAT TRADE	EQ 375MG BASE	N20353 001 Jan 05, 1996 Mar CTEC
+	EQ 500MG BASE	N20353 002 Jan 05, 1996 Mar CTEC
NAPROXEN SODIUM		
@ WATSON LABS FLORIDA	EQ 375MG BASE	N75416 002 Apr 23, 2003 Mar DISC
@	EQ 500MG BASE	N75416 001 Aug 27, 2002 Mar DISC

NIFEDIPINE

CAPSULE; ORAL
PROCARDIA

AB + PFIZER	10MG	N18482 001 Apr CRLD
@	20MG	N18482 002 Jul 24, 1986 Apr DISC
TABLET, EXTENDED RELEASE; ORAL		
ADALAT CC		
AB1 BAYER HLTHCARE	30MG	N20198 001 Apr 21, 1993 Jun CAHN
AB1 +	60MG	N20198 002 Apr 21, 1993 Jun CAHN
AB1 +	90MG	N20198 003 Apr 21, 1993 Jun CAHN

NIMODIPINE

CAPSULE; ORAL
NIMODIPINE

AB + BARR	30MG	N77811 001 May 02, 2007 Mar CRLD
NIMOTOP		
@ BAYER PHARMS	30MG	N18869 001 Dec 28, 1988 Feb DISC

NITISINONE

CAPSULE; ORAL
ORFADIN

RARE DIS	2MG	N21232 001 Jan 18, 2002 Mar CAHN
	5MG	N21232 002 Jan 18, 2002 Mar CAHN
+	10MG	N21232 003 Jan 18, 2002 Mar CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

@ SANDOZ	25MG	N74336 001 Jan 25, 1995 Mar DISC
@	50MG	N74336 002 Jan 25, 1995 Mar DISC
@	100MG	N74336 003 Jan 25, 1995 Mar DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

AT FDC LTD	0.3%	N78559 001 Feb 25, 2009 Feb NEWA
SOLUTION/DROPS; OTIC		
OFLOXACIN		
>A> AT PHARMAFORCE	0.3%	N90395 001 Aug 11, 2009 Jul NEWA
TABLET; ORAL		
FLOXIN		
@ ORTHO MCNEIL JANSSEN	200MG	N19735 001 Dec 28, 1990 Mar DISC
@	300MG	N19735 002 Dec 28, 1990 Mar DISC
@	400MG	N19735 003 Dec 28, 1990 Mar DISC
OFLOXACIN		
>D> AB RANBAXY	200MG	N76220 001 Sep 02, 2003 Jul DISC

TABLET; ORAL

OFLOXACIN

>A>	@ RANBAXY	200MG	N76220 001	Sep 02, 2003	Jul	DISC
>D> AB		300MG	N76220 002	Sep 02, 2003	Jul	DISC
>A>	@	300MG	N76220 002	Sep 02, 2003	Jul	DISC
>D> AB		400MG	N76220 003	Sep 02, 2003	Jul	DISC
>A>	@	400MG	N76220 003	Sep 02, 2003	Jul	DISC

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ ALAVEN PHARM	250MG	N19715 001	Jul 31, 1990	Apr	CAHN
+ UCB INC	250MG	N19715 001	Jul 31, 1990	Jun	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB DR REDDYS LABS	40MG	N78490 001	Apr 17, 2009	Mar	NEWA
AB DR REDDYS LABS LTD	10MG	N78693 001	Mar 16, 2009	Mar	NEWA
AB	20MG	N78693 002	Mar 16, 2009	Mar	NEWA
AB KREMERS URBAN DEV	40MG	N75410 003	Jan 23, 2009	Jan	NEWA

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD	20MG	N78878 001	Jun 05, 2009	May	NEWA
--------------------	------	------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP BEDFORD LABS	EQ 0.64MG BASE/ML	N78291 001	Apr 13, 2009	Mar	NEWA
-----------------	-------------------	------------	--------------	-----	------

ORLISTAT

CAPSULE; ORAL

XENICAL

>D> + HLR	120MG	N20766 001	Apr 23, 1999	Jul	CAHN
>A> + HOFFMANN LA ROCHE	120MG	N20766 001	Apr 23, 1999	Jul	CAHN

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

@ WATSON LABS	EQ 250MG BASE/VIAL	N62856 001	Oct 26, 1988	Apr	DISC
@	EQ 500MG BASE/VIAL	N62856 002	Oct 26, 1988	Apr	DISC
@	EQ 1GM BASE/VIAL	N62856 003	Oct 26, 1988	Apr	DISC
@	EQ 2GM BASE/VIAL	N62856 004	Oct 26, 1988	Apr	DISC
@	EQ 4GM BASE/VIAL	N62856 005	Oct 26, 1988	Apr	DISC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

>D> + SANOFI AVENTIS US	50MG/10ML (5MG/ML)	N21759 001	Jan 31, 2005	Jul	CFTG
>A> AP +	50MG/10ML (5MG/ML)	N21759 001	Jan 31, 2005	Jul	CFTG
>D> +	100MG/20ML (5MG/ML)	N21759 002	Jan 31, 2005	Jul	CFTG
>A> AP +	100MG/20ML (5MG/ML)	N21759 002	Jan 31, 2005	Jul	CFTG
>A> OXALIPLATIN					
>A> AP EBEWE PHARMA	50MG/10ML (5MG/ML)	N78812 001	Aug 07, 2009	Jul	NEWA

INJECTABLE; IV (INFUSION)

>A>	OXALIPLATIN												
>A> AP	EBEWE PHARMA		100MG/20ML (5MG/ML)		N78812	002	Aug 07,	2009	Jul	NEWA			
>A> AP	FRESENIUS KABI ONCOL		50MG/VIAL		N78810	001	Aug 07,	2009	Jul	NEWA			
>A> AP			100MG/VIAL		N78810	002	Aug 07,	2009	Jul	NEWA			
>A> AP	HOSPIRA WORLDWIDE		50MG/10ML (5MG/ML)		N78813	001	Aug 07,	2009	Jul	NEWA			
>A> AP			100MG/20ML (5MG/ML)		N78813	002	Aug 07,	2009	Jul	NEWA			
>A> AP	SUN PHARMA GLOBAL		50MG/VIAL		N78818	001	Aug 07,	2009	Jul	NEWA			
>A> AP			100MG/VIAL		N78818	002	Aug 07,	2009	Jul	NEWA			

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ SANDOZ

600MG

N75850 001 Apr 27, 2001 Mar DISC

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB	RANBAXY	300MG/5ML	N78734	001	Jun 26,	2009	Jun	NEWA					
AB	+ NOVARTIS	300MG/5ML	N21285	001	May 25,	2001	Jun	CFTG					

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT

400MG

N87863 001 May 24, 1983 Jun CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS	OXYBUTYNIN CHLORIDE	10%(100MG/PACKET)	N22204	001	Jan 27,	2009	Mar	CTNA					
+ WATSON LABS	OXYBUTYNIN CHLORIDE	10%(100MG/PACKET)	N22204	001	Jan 27,	2009	Jan	NEWA					
AB OSMOTICA PHARM	OXYBUTYNIN CHLORIDE	5MG	N78503	001	Feb 04,	2009	Jan	NEWA					
AB	OXYBUTYNIN CHLORIDE	10MG	N78503	002	Feb 04,	2009	Jan	NEWA					
AB	OXYBUTYNIN CHLORIDE	15MG	N78503	003	Feb 04,	2009	Jan	NEWA					

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB SUN PHARM IND INC	OXYCODONE HYDROCHLORIDE	5MG	N90659	001	Apr 10,	2009	Mar	NEWA					
AB	OXYCODONE HYDROCHLORIDE	15MG	N90659	002	Apr 10,	2009	Mar	NEWA					
AB	OXYCODONE HYDROCHLORIDE	30MG	N90659	003	Apr 10,	2009	Mar	NEWA					
AB VINTAGE PHARMS	OXYCODONE HYDROCHLORIDE	5MG	N77712	003	Mar 02,	2009	Mar	NEWA					
AB ROXICODONE	OXYCODONE HYDROCHLORIDE	5MG	N21011	003	May 15,	2009	May	NEWA					
AB XANODYNE PHARMS	OXYCODONE HYDROCHLORIDE	5MG											

PALIPERIDONE PALMITATE

>A>	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR												
>A>	INVEGA SUSTENNA												
>A> JOHNSON AND JOHNSON	OXYCODONE HYDROCHLORIDE	39MG/0.25ML (39MG/0.25ML)	N22264	001	Jul 31,	2009	Jul	NEWA					
>A>	OXYCODONE HYDROCHLORIDE	78MG/0.5ML (78MG/0.5ML)	N22264	002	Jul 31,	2009	Jul	NEWA					
>A>	OXYCODONE HYDROCHLORIDE	117MG/0.75ML (117MG/0.75ML)	N22264	003	Jul 31,	2009	Jul	NEWA					
>A>	OXYCODONE HYDROCHLORIDE	156MG/ML (156MG/ML)	N22264	004	Jul 31,	2009	Jul	NEWA					

>A>	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR				
>A>	INVEGA SUSTENNA				
>A>	JOHNSON AND JOHNSON 234MG/1.5ML (156MG/ML)		N22264 005 Jul 31, 2009 Jul NEWA		
	<u>PAMIDRONATE DISODIUM</u>				
	INJECTABLE; INJECTION				
	PAMIDRONATE DISODIUM				
AP	GENERAMEDIX 30MG/VIAL		N78300 001 Mar 10, 2009 Feb NEWA		
AP	90MG/VIAL		N78300 002 Mar 10, 2009 Feb NEWA		
	<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)</u>				
>D>	CAPSULE; ORAL				
>D>	CREON				
>D>	SOLVAY 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS		N20725 001 Apr 30, 2009 Jul CDFR		
	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS		N20725 001 Apr 30, 2009 Apr NEWA		
>D>	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS		N20725 002 Apr 30, 2009 Jul CDFR		
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS		N20725 002 Apr 30, 2009 Apr NEWA		
>D>	+ 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS		N20725 003 Apr 30, 2009 Jul CDFR		
	+ 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS		N20725 003 Apr 30, 2009 Apr NEWA		
>A>	CAPSULE, DELAYED RELEASE; ORAL				
>A>	CREON				
>A>	SOLVAY 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS		N20725 001 Apr 30, 2009 Jul CDFR		
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS		N20725 002 Apr 30, 2009 Jul CDFR		
>A>	+ 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS		N20725 003 Apr 30, 2009 Jul CDFR		
	<u>PANCURONIUM BROMIDE</u>				
	INJECTABLE; INJECTION				
	PANCURONIUM BROMIDE				
	@ HOSPIRA 2MG/ML		N72321 001 Jan 19, 1989 Apr DISC		
	<u>PANTOPRAZOLE SODIUM</u>				
	TABLET, DELAYED RELEASE; ORAL				
	PANTOPRAZOLE SODIUM				
AB	KUDCO IRELAND EQ 20MG BASE		N78281 001 Mar 17, 2009 Mar NEWA		
AB	EQ 40MG BASE		N78281 002 Mar 17, 2009 Mar NEWA		
	<u>PAROMOMYCIN SULFATE</u>				
	CAPSULE; ORAL				
	PAROMOMYCIN SULFATE				
>A>	AA HERITAGE PHARMS INC EQ 250MG BASE		N65173 001 Dec 14, 2007 Jul CAHN		
>D>	AA X-GEN PHARMS EQ 250MG BASE		N65173 001 Dec 14, 2007 Jul CAHN		
	<u>PENICILLIN G POTASSIUM</u>				
	INJECTABLE; INJECTION				
	PENICILLIN G POTASSIUM				
>A>	HANFORD GC 1,000,000 UNITS/VIAL		N65149 001 Jul 23, 2009 Jul NEWA		
>A>	AP 5,000,000 UNITS/VIAL		N65149 002 Jul 23, 2009 Jul NEWA		
>A>	AP 20,000,000 UNITS/VIAL		N65149 003 Jul 23, 2009 Jul NEWA		

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL
PENICILLIN-VK

AA + TEVA	EQ 250MG BASE/5ML	N60456 002	Apr CRLD
VEETIDS			
@ APOTHECON	EQ 125MG BASE/5ML	N61410 001	Mar DISC
@	EQ 250MG BASE/5ML	N61410 002	Mar DISC

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION
NEBUPENT
@ APP PHARMS 600MG/VIAL N19887 002 Mar 22, 1996 May DISC

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
NEMBUTAL SODIUM
+ LUNDBECK INC 50MG/ML N83246 001 Jun CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
@ SANDOZ 35MG N85695 001 May DISC

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN
AB WOCKHARDT EU 125MG/5ML N40420 001 Apr 19, 2002 Apr CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM
@ IVAX PHARMS 100MG PROMPT N80259 001 Jan DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
PILOCARPINE HYDROCHLORIDE
AB LANNETT 7.5MG N77220 002 May 06, 2009 Apr NEWA

PINDOLOL

TABLET; ORAL
PINDOLOL
@ SANDOZ 5MG N73608 001 Mar 29, 1993 Mar DISC
@ 10MG N73609 001 Mar 29, 1993 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

AA BRECKENRIDGE PHARM	17GM/SCOOPFUL	N77736 001 May 26, 2006 Jun CAHN
AA GAVIS PHARMS	17GM/SCOOPFUL	N77736 001 May 26, 2006 Jan CAHN
@ TEVA PHARMS	17GM/SCOOPFUL	N77445 001 May 04, 2006 Jan DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

AA NOVEL LABS INC 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N90019 001 May 27, 2009 May NEWA
1.2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLTYELY

+ BRAINTREE 227.1GM/PACKET;2.82GM/PACKET;6.36 GM/PACKET;5.53GM/PACKET;21.5GM/PA CKET N19011 002 Jun 02, 1992 May CTEC

AA + 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT N19011 001 Jul 13, 1984 May CFTG
+ 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT N19011 001 Jul 13, 1984 Mar CTEC

PEG 3350 AND ELECTROLYTES

AA NOVEL LABS INC 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT N90231 001 Jun 01, 2009 May NEWA

AA 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT N90186 001 Jun 01, 2009 May NEWA

FOR SUSPENSION; ORAL

CO-LAV

@ BOCA PHARMA 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 .84GM/BOT;22.72GM/BOT N73428 001 Jan 28, 1992 Mar DISC

GO-EVAC

@ BOCA PHARMA 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 .86GM/BOT;22.74GM/BOT N73433 001 Apr 28, 1992 Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

@ KV PHARM 8MEQ N18238 001 Feb DISC

MICRO-K 10

@ KV PHARM 10MEQ N18238 002 May 14, 1984 Feb DISC

POTASSIUM CHLORIDE

@ KV PHARM 10MEQ N70980 001 Feb 17, 1987 Feb DISC

WATSON LABS FLORIDA

8MEQ N77419 001 Jun 02, 2008 Feb CTEC

+ 10MEQ N77419 002 Jun 02, 2008 Feb CRLD

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ HOSPIRA 1.5MEQ/ML N83345 001 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB WATSON LABS FLORIDA 10MEQ N75604 001 Apr 10, 2002 May CRLD

AB + 10MEQ N75604 001 Apr 10, 2002 Jan CRLD

>A> PRASUGREL HYDROCHLORIDE

>A> TABLET; ORAL

>A> EFFIENT

>A> ELI LILLY AND CO EQ 5MG BASE

N22307 001 Jul 10, 2009 Jul NEWA

>A> + EQ 10MG BASE

N22307 002 Jul 10, 2009 Jul NEWA

PRAZIQUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE 600MG

N18714 001 Dec 29, 1982 Jun CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ SANDOZ	EQ 1MG BASE	N72576 001	May 16, 1989	Mar	DISC
@	EQ 2MG BASE	N72577 001	May 16, 1989	Mar	DISC
@	EQ 5MG BASE	N72578 001	May 16, 1989	Mar	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

>D> AA + ASCENT PEDS	EQ 15MG BASE/5ML	N75117 001	Dec 14, 2000	Jul	CAHN
>A> AA + SCIELE PHARMA INC	EQ 15MG BASE/5ML	N75117 001	Dec 14, 2000	Jul	CAHN

PREDNISOLONE SODIUM PHOSPHATE

AA AMNEAL PHARMS	EQ 15MG BASE/5ML	N78345 001	Mar 10, 2009	Feb	NEWA
AA VINTAGE	EQ 15MG BASE/5ML	N79010 001	May 26, 2009	May	NEWA

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

@ BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	N40065 001	Jul 29, 1994	Apr	DISC
-------------------	--------------------	------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

>D> MEDICIS	EQ 10MG BASE	N21959 001	Jun 01, 2006	Jul	CAHN
>D>	EQ 15MG BASE	N21959 002	Jun 01, 2006	Jul	CAHN
>D> +	EQ 30MG BASE	N21959 003	Jun 01, 2006	Jul	CAHN
>A> SCIELE PHARMA INC	EQ 10MG BASE	N21959 001	Jun 01, 2006	Jul	CAHN
>A>	EQ 15MG BASE	N21959 002	Jun 01, 2006	Jul	CAHN
>A> +	EQ 30MG BASE	N21959 003	Jun 01, 2006	Jul	CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

@ SANDOZ	10MG	N89983 001	Jan 12, 1989	Mar	DISC
@	50MG	N89984 001	Jan 12, 1989	Mar	DISC

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANESE PLAIN DENTAL

+ DENTSPLY PHARM	4%	N21382 001		Apr	CTNA
------------------	----	------------	--	-----	------

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

>D> AP PHARMAFORCE	50MG/ML	N90845 001	Jun 22, 2009	Jul	CTEC
>A> AO	50MG/ML	N90845 001	Jun 22, 2009	Jul	CTEC
AP	50MG/ML	N90845 001	Jun 22, 2009	Jun	NEWA

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA SUN PHARM IND'S INC	6.25MG/5ML	N40891 001	Mar 13, 2009	Mar	NEWA
------------------------	------------	------------	--------------	-----	------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

>D> AB SANDOZ	12.5MG	N84176 002	May 22, 2009	Jul	DISC
>A> @	12.5MG	N84176 002	May 22, 2009	Jul	DISC
AB	12.5MG	N84176 002	May 22, 2009	May	NEWA

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

>D>	+ ROXANE	7.5MG	N80927 001	Jul	DISC
>A>	@	7.5MG	N80927 001	Jul	DISC

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

AB	+ APP PHARMS	10MG/ML	N19627 002	Jun 11, 1996	Jun	CAHN
	@	10MG/ML	N19627 001	Oct 02, 1989	Jun	CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

AA	HERITAGE PHARMS INC	65MG	N80530 001	Mar	CMFD	
AA	PROPOXYPHENE HYDROCHLORIDE					
AA	VINTAGE PHARMS	65MG	N40908 001	Jul 17, 2009	Jun	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	UPSHER SMITH	60MG	N78311 001	Mar 06, 2009	Feb	NEWA
AB		80MG	N78311 002	Mar 06, 2009	Feb	NEWA
AB		120MG	N78311 003	Mar 06, 2009	Feb	NEWA
AB		160MG	N78311 004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ SANDOZ	10MG	N70663 001	Jun 13, 1986	Mar	DISC
@	20MG	N70664 001	Jun 13, 1986	Mar	DISC
@	40MG	N70665 001	Jun 13, 1986	Mar	DISC
@	60MG	N70666 001	Oct 10, 1986	Mar	DISC
@	80MG	N70667 001	Jun 13, 1986	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ SANDOZ	60MG; 2.5MG	N88602 001	Apr 11, 1985	Mar	DISC
+ SANDOZ	60MG; 2.5MG	N88193 001	May 17, 1983	Mar	CTEC

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	SUN PHARM IND LTD	EQ 5MG BASE	N90800 001	Jun 18, 2009	Jun	NEWA
AB		EQ 10MG BASE	N90800 002	Jun 18, 2009	Jun	NEWA
AB		EQ 20MG BASE	N90800 003	Jun 18, 2009	Jun	NEWA
AB		EQ 40MG BASE	N90800 004	Jun 18, 2009	Jun	NEWA

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB	RANBAXY	5MG	N78849 001	Mar 06, 2009	Feb	NEWA
AB		10MG	N78849 002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

@ BEDFORD EQ 25MG BASE/ML N74764 001 Nov 19, 2004 Apr DISC

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312 001 Sep 02, 2008 Feb CTNA
AA	DR REDDYS LABS LTD	EQ 15MG BASE/ML	N90102 001 May 26, 2009 May NEWA
AA	WOCKHARDT	EQ 15MG BASE/ML	N79211 001 May 26, 2009 May NEWA
AA		EQ 15MG BASE/ML	N79212 001 Feb 23, 2009 Feb NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	RANBAXY	EQ 150MG BASE	N75439 001 Apr 19, 2000 Jul DISC
>A>		@	EQ 150MG BASE	N75439 001 Apr 19, 2000 Jul DISC
>D>	AB		EQ 300MG BASE	N75439 002 Apr 19, 2000 Jul DISC
>A>		@	EQ 300MG BASE	N75439 002 Apr 19, 2000 Jul DISC

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

GILEAD	500MG	N21526 002 Jan 27, 2006 Jun CAHN
+	1GM	N21526 001 Feb 12, 2007 Jun CAHN

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

@ PROCTER AND GAMBLE 75MG N20835 004 Apr 16, 2007 May DISC

RISPERIDONE

SOLUTION; ORAL

RISPERDAL

AA	+	ORTHO MCNEIL JANSSEN	1MG/ML	N20588 001 Jun 10, 1996 Jan CFTG
RISPERIDONE				
>A>	AA	APOTEX INC	1MG/ML	N77719 001 Jul 29, 2009 Jul NEWA
>A>	AA	DR REDDYS LABS LTD	1MG/ML	N78909 001 Jul 29, 2009 Jul NEWA
>A>	AA	ROXANE	1MG/ML	N76904 001 Jul 29, 2009 Jul NEWA
AA		TEVA	1MG/ML	N76440 001 Jan 30, 2009 Jan NEWA

TABLET; ORAL

RISPERIDONE

AB	ACTAVIS TOTOWA	0.25MG	N78071 001 Jun 17, 2009 Jun NEWA
AB		0.5MG	N78071 002 Jun 17, 2009 Jun NEWA
AB		1MG	N78071 003 Jun 17, 2009 Jun NEWA
AB		2MG	N78071 004 Jun 17, 2009 Jun NEWA
AB		3MG	N78071 005 Jun 17, 2009 Jun NEWA
AB		4MG	N78071 006 Jun 17, 2009 Jun NEWA
AB	CADISTA PHARMS	0.25MG	N78828 001 Mar 23, 2009 Mar NEWA
AB		0.5MG	N78828 002 Mar 23, 2009 Mar NEWA
AB		1MG	N78828 003 Mar 23, 2009 Mar NEWA
AB		2MG	N78828 004 Mar 23, 2009 Mar NEWA
AB		3MG	N78828 005 Mar 23, 2009 Mar NEWA
AB		4MG	N78828 006 Mar 23, 2009 Mar NEWA
AB	WEST WARD PHARMS	0.25MG	N78740 001 May 29, 2009 May NEWA
AB		0.5MG	N78740 002 May 29, 2009 May NEWA
AB		1MG	N78740 003 May 29, 2009 May NEWA
AB		2MG	N78740 004 May 29, 2009 May NEWA

TABLET; ORALRISPERIDONE

AB	WEST WARD PHARMS	3MG	N78740 005	May 29, 2009	May	NEWA
AB		4MG	N78740 006	May 29, 2009	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORALRISPERDAL

AB	ORTHO MCNEIL JANSSEN	0.5MG	N21444 001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444 003	Apr 02, 2003	Feb	CFTG
AB		3MG	N21444 004	Dec 23, 2004	Apr	CFTG
AB		4MG	N21444 005	Dec 23, 2004	Apr	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328 001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328 003	Feb 24, 2009	Feb	NEWA
	KALI LABS	0.25MG	N77494 001	Apr 30, 2009	Apr	NEWA
AB		0.5MG	N77494 002	Apr 30, 2009	Apr	NEWA
AB		2MG	N77494 004	Apr 30, 2009	Apr	NEWA
AB		3MG	N77494 005	Apr 30, 2009	Apr	NEWA
AB		4MG	N77494 006	Apr 30, 2009	Apr	NEWA
	PAR PHARM	0.25MG	N77494 001	Apr 30, 2009	Jun	CAHN
AB		0.5MG	N77494 002	Apr 30, 2009	Jun	CAHN
AB		2MG	N77494 004	Apr 30, 2009	Jun	CAHN
AB		3MG	N77494 005	Apr 30, 2009	Jun	CAHN
AB		4MG	N77494 006	Apr 30, 2009	Jun	CAHN
AB	ZYDUS PHARMS USA	0.5MG	N78516 001	May 01, 2009	Apr	NEWA
AB		2MG	N78516 003	May 01, 2009	Apr	NEWA

RITODRINE HYDROCHLORIDEINJECTABLE; INJECTIONRITODRINE HYDROCHLORIDE

@ HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	Apr	DISC
@	15MG/ML	N71619 001	Feb 28, 1991	Apr	DISC
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
@ HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	Apr	DISC

ROPINIROLE HYDROCHLORIDETABLET; ORALROPINIROLE HYDROCHLORIDE

AB	HUAHAI US INC	EQ 0.25MG BASE	N78110 001	May 05, 2008	Apr	CAHN
AB		EQ 0.5MG BASE	N78110 002	May 05, 2008	Apr	CAHN
AB		EQ 1MG BASE	N78110 003	May 05, 2008	Apr	CAHN
AB		EQ 2MG BASE	N78110 004	May 05, 2008	Apr	CAHN
AB		EQ 3MG BASE	N78110 005	May 05, 2008	Apr	CAHN
AB		EQ 4MG BASE	N78110 006	May 05, 2008	Apr	CAHN
AB	ZYDUS PHARMS USA INC	EQ 0.25MG BASE	N90411 001	Jun 01, 2009	May	NEWA
AB		EQ 0.5MG BASE	N90411 002	Jun 01, 2009	May	NEWA
AB		EQ 1MG BASE	N90411 003	Jun 01, 2009	May	NEWA
AB		EQ 2MG BASE	N90411 004	Jun 01, 2009	May	NEWA
AB		EQ 3MG BASE	N90411 005	Jun 01, 2009	May	NEWA
AB		EQ 4MG BASE	N90411 006	Jun 01, 2009	May	NEWA
AB		EQ 5MG BASE	N90411 007	Jun 01, 2009	May	NEWA

TABLET, EXTENDED RELEASE; ORALREQUIP XL

SMITHKLINE BEECHAM	EQ 6MG BASE	N22008 006	Apr 10, 2009	Apr	NEWA
--------------------	-------------	------------	--------------	-----	------

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ EUSA PHARMA USA 50mCi/ML

N20570 001 Mar 28, 1997 May CAHN

>A> SAXAGLIPTIN HYDROCHLORIDE

>A> TABLET; ORAL

>A> ONGLYZA

>A> BRISTOL MYERS SQUIBB EQ 2.5MG BASE

N22350 001 Jul 31, 2009 Jul NEWA

>A> + EQ 5MG BASE

N22350 002 Jul 31, 2009 Jul NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ ENDO PHARMS 5MG

N74565 001 Aug 02, 1996 Apr DISC

@ SIEGFRIED 5MG

N74672 001 Apr 01, 1997 Apr DISC

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

>A> + ORTHO DERMATOLOGICS 2%

N21385 001 Dec 10, 2003 Jul CAHN

>D> + ORTHONEUTROGENA 2%

N21385 001 Dec 10, 2003 Jul CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB AUSTARPHARMA LLC EQ 25MG BASE

N78677 001 Mar 04, 2009 Feb NEWA

AB EQ 50MG BASE

N78677 002 Mar 04, 2009 Feb NEWA

AB EQ 100MG BASE

N78677 003 Mar 04, 2009 Feb NEWA

>A> AB HIKMA PHARMS EQ 25MG BASE

N77864 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE

N77864 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE

N77864 003 Aug 10, 2009 Jul NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB LUPIN 5MG

N78103 005 Apr 14, 2009 Mar NEWA

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL

SODIUM PHOSPHATE P 32

@ MALLINCKRODT 0.67mCi/ML

N11777 001 May DISC

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

AA KVK TECH 454GM/BOT

N40905 001 Mar 30, 2009 Mar NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

>D> + CANGENE 5MG/ML (5MG/ML)

N21538 001 Jan 23, 2008 Jul DISC

>A> @ 5MG/ML (5MG/ML)

N21538 001 Jan 23, 2008 Jul DISC

NORDITROPIN NORDIFLEX

NOVO NORDISK INC 30MG/3ML

N21148 007 Mar 10, 2009 Mar NEWA

INJECTABLE; INJECTION

SEROSTIM

>D>	EMD SERONO	8 .8MG/VIAL	N20604 004 Sep 06, 2001 Jul DISC
>A>	@	8 .8MG/VIAL	N20604 004 Sep 06, 2001 Jul DISC

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+ BAYER HLTHCARE	EQ 200MG BASE	N21923 001 Dec 20, 2005 Jun CAHN
------------------	---------------	----------------------------------

SOTALOL HYDROCHLORIDE

>A>	SOLUTION; INTRAVENOUS		
>A>	SOTALOL HYDROCHLORIDE		
>A>	+ ACADEMIC PHARMS	150MG/10ML (15MG/ML)	N22306 001 Jul 02, 2009 Jul NEWA

STANOZOLOL

TABLET; ORAL

WINSTROL

@ LUNDBECK INC

2MG

N12885 001 May 14, 1984 Mar CAHN

STAVUDINE

FOR SOLUTION; ORAL

STAVUDINE

AA	CIPLA LTD	1MG/ML	N78030 001 Mar 20, 2009 Mar NEWA
----	-----------	--------	----------------------------------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK INC	100MG	N19998 002 Jan 30, 1991 Mar CAHN
----------------	-------	----------------------------------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	PERRIGO CO TENNESSEE	10%	N78649 001 Mar 23, 2009 Mar NEWA
AB	TARO	10%	N78668 001 May 20, 2009 May NEWA

SOLUTION/DROPS; OPHTHALMIC

SULF-10

@ NOVARTIS

10%

N80025 001 Apr DISC

SULFACETAMIDE SODIUM

@ ALCON

30%

N89068 001 May 05, 1987 Apr DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOPRIM

AB	PAR PHARM	400MG;80MG	N70022 001 Feb 15, 1985 Mar CMFD
----	-----------	------------	----------------------------------

SULFAMETHOPRIM-DS

AB	PAR PHARM	800MG;160MG	N70032 001 Feb 15, 1985 Mar CMFD
----	-----------	-------------	----------------------------------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ SANDOZ

800MG;160MG

N70890 001 Nov 13, 1986 Mar DISC

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

@ ROCHE

EQ 500MG BASE/5ML

N09182 004

Jun DISC

SULINDAC

TABLET; ORAL

SULINDAC

@ SANDOZ

150MG

N72712 001 Aug 30, 1991 Mar DISC

@

200MG

N72713 001 Aug 30, 1991 Mar DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

AP + GLAXOSMITHKLINE EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N20080 001 Dec 28, 1992 Jan CFTG

SUMATRIPTAN SUCCINATE

AP APP PHARMS EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N79242 001 Mar 02, 2009 Feb NEWAAP BEDFORD EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N79123 001 Feb 06, 2009 Jan NEWAAP JHP PHARMS EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N77871 001 Jul 09, 2009 Jun NEWAAP SANDOZ EQ 4MG BASE/0.5ML (EQ 8MG
BASE/ML) N78067 002 Feb 06, 2009 Jan NEWAAP EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N78067 001 Feb 06, 2009 Jan NEWAAP TEVA PARENTERAL EQ 4MG BASE/0.5ML (EQ 8MG
BASE/ML) N78318 001 Feb 06, 2009 Jan NEWAAP EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N78318 002 Feb 06, 2009 Jan NEWAAP EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N77907 001 Feb 06, 2009 Jan NEWAAP WOCKHARDT EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) N78593 001 Feb 06, 2009 Jan NEWA

>A> SUMAVEL DOSEPRO

>A> + ZOGENIX INC EQ 6MG BASE/0.5ML (EQ 6MG
BASE/0.5ML) N22239 001 Jul 15, 2009 Jul NEWA

TABLET; ORAL

IMITREX

AB GLAXOSMITHKLINE EQ 25MG BASE N20132 002 Jun 01, 1995 Jan CFTG

AB EQ 50MG BASE N20132 003 Jun 01, 1995 Jan CFTG

AB + EQ 100MG BASE N20132 001 Jun 01, 1995 Jan CFTG

SUMATRIPTAN SUCCINATE

>A> AB AUROBINDO PHARMA EQ 25MG BASE N78327 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N78327 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE N78327 003 Aug 10, 2009 Jul NEWA

>A> AB COBALT LABS INC EQ 25MG BASE N76933 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N76933 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE N76933 003 Aug 10, 2009 Jul NEWA

>A> AB DR REDDYS LABS INC EQ 25MG BASE N76847 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N76847 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE N76847 003 Aug 10, 2009 Jul NEWA

>A> AB MYLAN EQ 25MG BASE N77744 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N77744 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE N77744 003 Aug 10, 2009 Jul NEWA

>A> AB ORCHID HLTHCARE EQ 25MG BASE N78284 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N78284 002 Aug 10, 2009 Jul NEWA

>A> AB EQ 100MG BASE N78284 003 Aug 10, 2009 Jul NEWA

>A> AB RANBAXY EQ 25MG BASE N76554 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N76554 002 Aug 10, 2009 Jul NEWA

AB EQ 100MG BASE N76572 001 Feb 09, 2009 Jan NEWA

>A> AB ROXANE EQ 25MG BASE N78241 001 Aug 10, 2009 Jul NEWA

>A> AB EQ 50MG BASE N78241 002 Aug 10, 2009 Jul NEWA

TABLET; ORALSUMATRIPTAN SUCCINATE

>A>	AB	ROXANE	EQ 100MG BASE	N78241 003 Aug 10, 2009 Jul NEWA
>A>	AB	SANDOZ	EQ 25MG BASE	N76976 001 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 50MG BASE	N76976 002 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 100MG BASE	N76976 003 Aug 10, 2009 Jul NEWA
>A>	AB	SUN PHARM INDS	EQ 25MG BASE	N78295 001 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 50MG BASE	N78295 002 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 100MG BASE	N78295 003 Aug 10, 2009 Jul NEWA
	AB	TEVA	EQ 25MG BASE	N76840 001 Feb 09, 2009 Jan NEWA
	AB		EQ 50MG BASE	N76840 002 Feb 09, 2009 Jan NEWA
	AB		EQ 100MG BASE	N76840 003 Feb 09, 2009 Jan NEWA

SUNITINIB MALATECAPSULE; ORALSUTENT

CPPI CV	EQ 37.5MG BASE	N21938 004 Mar 31, 2009 Mar NEWA
---------	----------------	----------------------------------

TACROLIMUSCAPSULE; ORALPROGRAF

>D>		ASTELLAS	EQ 0.5MG BASE	N50708 003 Aug 24, 1998 Jul CFTG
>A>	AB		EQ 0.5MG BASE	N50708 003 Aug 24, 1998 Jul CFTG
>D>			EQ 1MG BASE	N50708 001 Apr 08, 1994 Jul CFTG
>A>	AB		EQ 1MG BASE	N50708 001 Apr 08, 1994 Jul CFTG
>D>	+		EQ 5MG BASE	N50708 002 Apr 08, 1994 Jul CFTG
>A>	AB	+	EQ 5MG BASE	N50708 002 Apr 08, 1994 Jul CFTG
>A>		TACROLIMUS		
>A>	AB	SANDOZ	EQ 0.5MG BASE	N65461 001 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 1MG BASE	N65461 002 Aug 10, 2009 Jul NEWA
>A>	AB		EQ 5MG BASE	N65461 003 Aug 10, 2009 Jul NEWA

TadalafilTABLET; ORALADCIRCA

+ ELI LILLY CO	20MG	N22332 001 May 22, 2009 May NEWA
----------------	------	----------------------------------

TAMOXIFEN CITRATETABLET; ORALTAMOXIFEN CITRATE

@ ROXANE	EQ 10MG BASE	N76027 001 Feb 20, 2003 Mar DISC
@	EQ 20MG BASE	N76027 002 Feb 20, 2003 Mar DISC

TAPENTADOL HYDROCHLORIDETABLET; ORALTAPENTADOL HYDROCHLORIDE

ORTHO MCNEIL JANSSEN	EQ 50MG BASE	N22304 001 Nov 20, 2008 Jun CPOT
	EQ 75MG BASE	N22304 002 Nov 20, 2008 Jun CPOT
+	EQ 100MG BASE	N22304 003 Nov 20, 2008 Jun CPOT

TECHNETIUM TC-99M BICISATE KITINJECTABLE; INJECTIONNEUROLITE

LANTHEUS MEDCL	N/A	N20256 001 Nov 23, 1994 Apr CPOT
----------------	-----	----------------------------------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

+ DRAXIMAGE	N/A	N18035 001	Apr	CTEC
>D> DRAXIMAGE MDP-25				
>D> + DRAXIMAGE	N/A	N18035 002	Feb 27, 2004	Jul DISC
>A> @	N/A	N18035 002	Feb 27, 2004	Jul DISC
+	N/A	N18035 002	Feb 27, 2004	Jun CMFD
@	N/A	N18035 002	Feb 27, 2004	Apr DISC
TECHNETIUM TC 99M MPI MDP				
@ GE HEALTHCARE	N/A	N18141 002	Jun 12, 1989	Apr DISC
@	N/A	N18141 001		Apr DISC

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP CARDINAL HEALTH 414	N/A	N78809 001	Apr 28, 2009	Apr NEWA
AP DRAXIMAGE	N/A	N78806 001	Apr 29, 2009	Apr NEWA
AP PHARMALUCENCE	N/A/VIAL	N79157 001	Jul 10, 2009	Jun NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW 30ML

>D> @ GE HEALTHCARE	N/A	N20372 002	Jul 07, 2005	Jul CMFD
>A> +	N/A	N20372 002	Jul 07, 2005	Jul CMFD

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

+ NOVARTIS	100MG/5ML	N22154 001	Apr 28, 2009	Apr NEWA
-----------------	-----------	------------	--------------	----------

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

AB TYCO HLTHCARE	22.5MG	N18163 004	Nov 02, 2004	Jun CFTG
AB TEMAZEPAM				
AB MYLAN	22.5MG	N70920 003	Jun 12, 2009	Jun NEWA

@ NOVEL LABS INC

30MG

N71457 001 Apr 21, 1987 Mar CAHN

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

+ SCHERING	100MG/VIAL	N22277 001	Feb 27, 2009	Feb NEWA
-----------------	------------	------------	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB IVAX PHARMS	EQ 1MG BASE	N75614 002	Jan 30, 2001	May CMFD
AB	EQ 2MG BASE	N75614 001	Jan 30, 2001	May CMFD
AB	EQ 5MG BASE	N75614 003	Jan 30, 2001	May CMFD
AB	EQ 10MG BASE	N75614 004	Jan 30, 2001	May CMFD

TABLET; ORAL

HYTRIN

ABBOTT

+ ABBOTT	EQ 1MG BASE	N19057 001	Aug 07, 1987	Mar CTEC
+ ABBOTT	EQ 2MG BASE	N19057 002	Aug 07, 1987	Mar CTEC

TABLET; ORAL

HYTRIN

ABBOTT	EQ 5MG BASE	N19057 003	Aug 07, 1987	Mar	CTEC
	EQ 10MG BASE	N19057 004	Aug 07, 1987	Mar	CTEC
TERAZOSIN HYDROCHLORIDE					
@ SANDOZ	EQ 1MG BASE	N74315 001	Dec 31, 1998	Mar	DISC
@	EQ 2MG BASE	N74315 002	Dec 31, 1998	Mar	DISC
@	EQ 5MG BASE	N74315 003	Dec 31, 1998	Mar	DISC
@	EQ 10MG BASE	N74315 004	Dec 31, 1998	Mar	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP	HIKMA FARMACEUTICA	1MG/ML	N78630 001	May 20, 2009	May	NEWA
----	--------------------	--------	------------	--------------	-----	------

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318 002	Jun 25, 2008	Feb	NEWA
+	0.75MG/3ML (0.25MG/ML)	N21318 001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

UNIMED PHARMS	1% (2.5GM/PACKET)	N21015 001	Feb 28, 2000	Mar	CTEC
BX +	1% (5GM/PACKET)	N21015 002	Feb 28, 2000	Mar	CTEC
TESTOSTERONE					
@ WATSON LABS	1% (2.5GM/PACKET)	N76737 001	Jan 27, 2006	Mar	DISC
@	1% (5GM/PACKET)	N76737 002	Jan 27, 2006	Mar	DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

AO + ENDO PHARM	200MG/ML	N09165 003	Apr	CAHN
@	200MG/ML	N09165 001	Apr	CAHN
AO + ENDO PHARMS	200MG/ML	N09165 003	Mar	CAHN
@	200MG/ML	N09165 001	Mar	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+ NYCOMED US	0.05%	N86576 002	Apr	CAHN
	0.1%	N86576 001	Apr	CAHN

SPRAY; NASAL

TYZINE

+ NYCOMED US	0.1%	N86576 003	Apr	CAHN
--------------	------	------------	-----	------

THEOPHYLLINE

ELIXIR; ORAL

ELIXOPHYLLIN

+ FOREST LABS	80MG/15ML	N85186 001	Jun	CRLD	
THEOPHYLLINE					
@ MORTON GROVE	80MG/15ML	N86748 001	Jun	DISC	
@ PRECISION DOSE	80MG/15ML	N85863 001	Jun	DISC	
AA @ TARO	80MG/15ML	N85863 001	Apr	CAHN	
	80MG/15ML	N89626 001	Oct 28, 1988	Jun	DISC

SOLUTION; ORAL THEOPHYLLINE @ ROXANE	80MG/15ML	N87449 001 Sep 15, 1983 Mar DISC
<u>THIABENDAZOLE</u>		
TABLET, CHEWABLE; ORAL MINTEZOL @ MERCK	500MG	N16096 001 Jun DISC
<u>THIOTHIXENE</u>		
CAPSULE; ORAL NAVANE @ PFIZER	20MG	N16584 005 Jun DISC
<u>TICLOPIDINE HYDROCHLORIDE</u>		
TABLET; ORAL TICLID @ ROCHE PALO	250MG	N19979 002 Oct 31, 1991 Jun DISC
TICLOPIDINE HYDROCHLORIDE AB + TEVA	250MG	N75149 001 Aug 20, 1999 Jun CRLD
<u>TIMOLOL MALEATE</u>		
SOLUTION/DROPS; OPHTHALMIC TIMOPTIC		
AT + ATON	EQ 0.25% BASE	N18086 001 Feb CAHN
AT +	EQ 0.5% BASE	N18086 002 Feb CAHN
TIMOPTIC IN OCUDOSE + ATON	EQ 0.25% BASE	N19463 001 Nov 05, 1986 Feb CAHN
+ @	EQ 0.5% BASE	N19463 002 Nov 05, 1986 Feb CAHN
SOLUTION, GEL FORMING/DROPS; OPHTHALMIC TIMOPTIC-XE		
AB + ATON	EQ 0.25% BASE	N20330 001 Nov 04, 1993 Feb CAHN
AB +	EQ 0.5% BASE	N20330 002 Nov 04, 1993 Feb CAHN
TABLET; ORAL TIMOLOL MALEATE		
MYLAN	5MG	N72666 001 Jun 08, 1990 Mar CTEC
	10MG	N72667 001 Jun 08, 1990 Mar CTEC
+	20MG	N72668 001 Jun 08, 1990 Mar CTEC
@ SANDOZ	5MG	N72550 001 Apr 13, 1989 Mar DISC
@	10MG	N72551 001 Apr 13, 1989 Mar DISC
@	20MG	N72552 001 Apr 13, 1989 Mar DISC
<u>TOLAZAMIDE</u>		
TABLET; ORAL TOLAZAMIDE		
IVAX PHARMS	100MG	N18894 001 Nov 02, 1984 Mar CTEC
>D> IVAX SUB TEVA PHARMS	100MG	N18894 001 Nov 02, 1984 Jul DISC
>A> @	100MG	N18894 001 Nov 02, 1984 Jul DISC
>D> AB	250MG	N18894 002 Nov 02, 1984 Jul DISC
>A> @	250MG	N18894 002 Nov 02, 1984 Jul DISC
>D> AB +	500MG	N18894 003 Nov 02, 1984 Jul DISC
>A> @	500MG	N18894 003 Nov 02, 1984 Jul DISC
>D> AB MYLAN	500MG	N70913 001 Mar 17, 1986 Jul CRLD
>A> AB +	500MG	N70913 001 Mar 17, 1986 Jul CRLD
@ SANDOZ	100MG	N71633 001 Dec 09, 1987 Mar DISC
@	250MG	N70289 001 Mar 13, 1986 Mar DISC

TABLET; ORAL

TOLAZAMIDE
@ SANDOZ

500MG

N70290 001 Mar 13, 1986 Mar DISC

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE
@ SANDOZ

500MG

N86574 001 Mar DISC

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM
@ SANDOZ

EQ 200MG BASE

N73588 001 Jul 31, 1992 Mar DISC

@

EQ 600MG BASE

N74002 001 Sep 27, 1993 Mar DISC

TOLVAPtan

TABLET; ORAL

SAMSCA
OTSUKA AMERICA PHARM

+

15MG

N22275 001 May 19, 2009 May NEWA

30MG

N22275 002 May 19, 2009 May NEWA

@

60MG

N22275 003 May 19, 2009 May DISC

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX
ORTHO MCNEIL JANSSEN

AB 15MG

N20844 001 Oct 26, 1998 Mar CFTG

AB + 25MG

N20844 002 Oct 26, 1998 Mar CFTG

TOPIRAMATE
BARR

AB 15MG

N76448 001 Apr 15, 2009 Mar NEWA

AB 25MG

N76448 002 Apr 15, 2009 Mar NEWA

AB COBALT LABS INC 15MG

N77868 001 Apr 15, 2009 Mar NEWA

AB 25MG

N77868 002 Apr 15, 2009 Mar NEWA

AB TEVA 15MG

N76575 001 Apr 17, 2009 Mar NEWA

AB 25MG

N76575 002 Apr 17, 2009 Mar NEWA

TABLET; ORAL

TOPAMAX
ORTHO MCNEIL JANSSEN

AB + 25MG

N20505 004 Dec 24, 1996 Mar CFTG

AB 50MG

N20505 005 Dec 24, 1996 Mar CFTG

AB 100MG

N20505 001 Dec 24, 1996 Mar CFTG

AB 200MG

N20505 002 Dec 24, 1996 Mar CFTG

TOPIRAMATE
APOTEX INC

AB 25MG

N77733 001 Mar 27, 2009 Mar NEWA

AB 50MG

N77733 002 Mar 27, 2009 Mar NEWA

AB 100MG

N77733 003 Mar 27, 2009 Mar NEWA

AB 200MG

N77733 004 Mar 27, 2009 Mar NEWA

AB AUROBINDO PHARMA 25MG

N78462 001 Mar 27, 2009 Mar NEWA

AB 50MG

N78462 002 Mar 27, 2009 Mar NEWA

AB 100MG

N78462 003 Mar 27, 2009 Mar NEWA

AB 200MG

N78462 004 Mar 27, 2009 Mar NEWA

AB BARR 25MG

N76315 001 Mar 27, 2009 Mar NEWA

AB 100MG

N76315 002 Mar 27, 2009 Mar NEWA

AB 200MG

N76315 003 Mar 27, 2009 Mar NEWA

AB CIPLA LTD 25MG

N76343 001 Mar 27, 2009 Mar NEWA

AB 50MG

N76343 002 Mar 27, 2009 Mar NEWA

AB 100MG

N76343 003 Mar 27, 2009 Mar NEWA

AB 200MG

N76343 004 Mar 27, 2009 Mar NEWA

TABLET; ORAL

TOPIRAMATE

AB	COBALT LABS INC	25MG	N77643 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77643 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77643 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77643 004	Mar 27, 2009	Mar	NEWA
AB	GLENMARK GENERICS	25MG	N77627 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77627 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77627 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77627 004	Mar 27, 2009	Mar	NEWA
AB	INVAGEN PHARMS	25MG	N79162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79162 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79162 004	Mar 27, 2009	Mar	NEWA
AB	MYLAN	25MG	N76314 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76314 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76314 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76314 004	Mar 27, 2009	Mar	NEWA
AB	PAR PHARM	25MG	N76311 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76311 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76311 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76311 004	Mar 27, 2009	Mar	NEWA
AB	PLIVA HRVATSKA DOO	25MG	N77905 001	Mar 30, 2009	Mar	NEWA
AB		50MG	N77905 002	Mar 30, 2009	Mar	NEWA
AB		100MG	N77905 003	Mar 30, 2009	Mar	NEWA
AB		200MG	N77905 004	Mar 30, 2009	Mar	NEWA
AB	RANBAXY	25MG	N76327 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76327 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76327 003	Mar 27, 2009	Mar	NEWA
AB	ROXANE	25MG	N76306 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76306 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76306 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76306 004	Mar 27, 2009	Mar	NEWA
AB	SUN PHARM INDS LTD	25MG	N90278 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90278 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90278 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N90278 004	Mar 27, 2009	Mar	NEWA
AB	TEVA	25MG	N76317 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76317 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76317 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76317 004	Mar 27, 2009	Mar	NEWA
AB	TORRENT PHARMS	25MG	N79153 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79153 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79153 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79153 004	Mar 27, 2009	Mar	NEWA
AB	UNICHEM	25MG	N90162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90162 003	Mar 27, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	25MG	N78235 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78235 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78235 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78235 004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB	HETERO DRUGS	5MG	N79234 001	Jan 27, 2009	Jan	NEWA
AB		10MG	N79234 002	Jan 27, 2009	Jan	NEWA
AB		20MG	N79234 003	Jan 27, 2009	Jan	NEWA
AB		100MG	N79234 004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
RYZOLT

BC	+ PURDUE PHARMA	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
BC		200MG	N21745 002	Dec 30, 2008	Mar	CAHN
BC		300MG	N21745 003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE
@ ETHYPHARM NORTH 50MG N21693 001 May 05, 2005 Mar CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

AB	ALVOGEN	50MG	N71636 001	Apr 18, 1988	Feb	CAHN
AB		100MG	N71514 001	Apr 18, 1988	Feb	CAHN
AB	APOTEX INC	300MG	N71196 003	Apr 26, 1999	May	CTEC
AB	MATRIX LABS LTD	50MG	N90514 001	Jun 02, 2009	May	NEWA
AB		100MG	N90514 002	Jun 02, 2009	May	NEWA
AB		150MG	N90514 003	Jun 02, 2009	May	NEWA
AB		300MG	N90514 004	Jun 02, 2009	May	NEWA
@	SANDOZ	50MG	N72484 001	Apr 30, 1990	Mar	DISC
@		100MG	N72483 001	Apr 30, 1990	Mar	DISC

TREPROSTINIL SODIUM

>A> SOLUTION; INHALATION
>A> TYVASO
>A> + UNITED THERAP EQ 0.6MG BASE/ML N22387 001 Jul 30, 2009 Jul NEWA

TRETINOIN

CREAM; TOPICAL
RENOVA

>D>	+ JOHNSON AND JOHNSON	0.02%	N21108 001	Aug 31, 2000	Jul	CAHN
>D>	AB2 +	0.05%	N19963 001	Dec 29, 1995	Jul	CAHN
>A>	+ ORTHO DERMATOLOGICS	0.02%	N21108 001	Aug 31, 2000	Jul	CAHN
>A>	AB2 +	0.05%	N19963 001	Dec 29, 1995	Jul	CAHN

GEL; TOPICAL
ATRALIN

+ DOW PHARM SCIENCES	0.05%	N22070 001	Jul 26, 2007	Jun	CAHN
----------------------	-------	------------	--------------	-----	------

RETIN-A MICRO

+ JOHNSON AND JOHNSON	0.04%	N20475 002	May 10, 2002	Jul	CAHN
+	0.1%	N20475 001	Feb 07, 1997	Jul	CAHN
+ ORTHO DERMATOLOGICS	0.04%	N20475 002	May 10, 2002	Jul	CAHN
+	0.1%	N20475 001	Feb 07, 1997	Jul	CAHN

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION						
KENALOG-10						
AB	APOTHECON	10MG/ML	N12041	001	May CFTG	
	KENALOG-40					
AB	+ APOTHECON	40MG/ML	N14901	001	May CFTG	
TRIAMCINOLONE ACETONIDE						
AB	SANDOZ	10MG/ML	N90166	001	May 27, 2009 May NEWA	
AB		40MG/ML	N90164	001	May 27, 2009 May NEWA	
SPRAY, METERED; NASAL						
NASACORT AQ						
>D>	+ SANOFI AVENTIS US	0.055MG/SPRAY	N20468	001	May 20, 1996 Jul CFTG	
>A> AB	+	0.055MG/SPRAY	N20468	001	May 20, 1996 Jul CFTG	
>A>	TRIAMCINOLONE ACETONIDE					
>A> AB	BARR	0.055MG/SPRAY	N78104	001	Jul 30, 2009 Jul NEWA	

TROSPiUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
SANCTURA XR					
+	ALLERGAN	60MG	N22103	001	Aug 03, 2007 Apr CAHN
+	ENDO PHARMS	60MG	N22103	001	Aug 03, 2007 Mar CAHN
TABLET; ORAL					
SANCTURA					
+	ALLERGAN	20MG	N21595	001	May 28, 2004 Apr CAHN
+	ENDO PHARMS	20MG	N21595	001	May 28, 2004 Mar CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC					
MEMBRANEBLUE					
+	DORC	0.15%	N22278	001	Feb 20, 2009 Feb NEWA

URSODIOL

TABLET; ORAL					
URSO 250					
AB	AXCAN	250MG	N20675	001	Dec 10, 1997 May CFTG
URSO FORTE					
AB	+ AXCAN	500MG	N20675	002	Jul 21, 2004 May CFTG
URSODIOL					
AB	TEVA PHARMS	250MG	N79184	001	May 13, 2009 May NEWA
AB		500MG	N79184	002	May 13, 2009 May NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL					
VALSTAR PRESERVATIVE FREE					
+	ENDO PHARM	40MG/ML	N20892	001	Sep 25, 1998 Apr CAHN
+	ENDO PHARMS	40MG/ML	N20892	001	Sep 25, 1998 Mar CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION					
VANCOMYCIN HYDROCHLORIDE					
AP	+ ABRAXIS PHARM	EQ 10GM BASE/VIAL	N62663	004	Nov 28, 1997 Apr CTEC
AP	HOSPIRA	EQ 750MG BASE/VIAL	N62912	002	Jan 07, 2009 May CTEC
AP		EQ 750MG BASE/VIAL	N62933	002	May 27, 2009 May NEWA
AP	HOSPIRA INC	EQ 10GM BASE/VIAL	N65455	001	Apr 29, 2009 Apr NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	SUN PHARMA GLOBAL	10MG/VIAL	N79001 001 Jun 17, 2009 Jun NEWA
AP		20MG/VIAL	N79001 002 Jun 17, 2009 Jun NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE
@ BEDFORD 2.5MG/ML

TABLET; ORAL
VERAPAMIL HYDROCHLORIDE
@ SANDOZ 40MG N73168 001 Jul 31, 1992 Mar DISC
@ 80MG N71423 001 May 24, 1988 Mar DISC
@ 120MG N71424 001 May 25, 1988 Mar DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

>A>	AP	ACTAVIS TOTOWA	EQ 10MG BASE/ML N78011 001 Jul 22, 2009 Jul NEWA
-----	----	----------------	--

ZIDOVUDINE

TABLET; ORAL
ZIDOVUDINE

>A>		@ AUROBINDO PHARMA	60MG N22294 001 Jul 23, 2009 Jul DISC
-----	--	--------------------	---------------------------------------

ZOLPIDEM TARTRATE

TABLET; SUBLINGUAL
EDLUAR

>A>		MEDA PHARMS	5MG N21997 001 Mar 13, 2009 Jul CAHN
>A>	+		10MG N21997 002 Mar 13, 2009 Jul CAHN
>D>		OREXO AB	5MG N21997 001 Mar 13, 2009 Jul CAHN
			5MG N21997 001 Mar 13, 2009 Jun CAHN
>D>	+		5MG N21997 001 Mar 13, 2009 Mar NEWA
	+		10MG N21997 002 Mar 13, 2009 Jul CAHN
	+		10MG N21997 002 Mar 13, 2009 Jun CAHN
	+		10MG N21997 002 Mar 13, 2009 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE
@ MUTUAL PHARM 25MG N77635 001 Dec 22, 2005 May DISC
@ 50MG N77635 002 Dec 22, 2005 May DISC
@ 100MG N77635 003 Dec 22, 2005 May DISC

OTC DRUG PRODUCT LIST - 29TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

N76200 001 Mar 19, 2002 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	BANNER PHARMACAPS	5MG	N22429 001 Jul 23, 2009 Jul NEWA
>A>		5MG	N22429 003 Jul 23, 2009 Jul NEWA
	CETIRIZINE HYDROCHLORIDE HIVES		
>A>	+ BANNER PHARMACAPS	10MG	N22429 002 Jul 23, 2009 Jul NEWA
>A>		10MG	N22429 004 Jul 23, 2009 Jul NEWA

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 5MG/5ML

N90474 002 Mar 30, 2009 Mar NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

DR REDDYS LABS LTD 5MG/5ML

N90474 001 Mar 30, 2009 Mar NEWA

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	CARACO	5MG	N77631 004 Jan 11, 2008 Jul NEWA
>A>		10MG	N77631 003 Jan 11, 2008 Jul NEWA
	CETIRIZINE HYDROCHLORIDE HIVES RELIEF		
>A>	CARACO	5MG	N77631 001 Jan 11, 2008 Jul CDFR
>A>		10MG	N77631 002 Jan 11, 2008 Jul CDFR

>D> TABLET; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	CARACO	5MG	N77631 001 Jan 11, 2008 Jul CDFR
>D>		10MG	N77631 002 Jan 11, 2008 Jul CDFR

CETIRIZINE HYDROCHLORIDE ALLERGY

ORCHID HLTHCARE 5MG
10MGN78862 001 Feb 19, 2009 Feb NEWA
N78862 002 Feb 19, 2009 Feb NEWA

>A>	TARO	5MG	N78072 003 Jul 22, 2009 Jul NEWA
>A>		5MG	N78072 001 Jul 22, 2009 Jul NEWA
	UNICHEM	5MG	N78680 003 Jun 26, 2009 Jun NEWA
		10MG	N78680 004 Jun 26, 2009 Jun NEWA

CETIRIZINE HYDROCHLORIDE HIVES

ORCHID HLTHCARE 5MG
10MG
UNICHEM 5MG
10MGN78862 003 Feb 19, 2009 Feb NEWA
N78862 004 Feb 19, 2009 Feb NEWA
N78680 001 Jun 26, 2009 Jun NEWA
N78680 002 Jun 26, 2009 Jun NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	TARO	10MG	N78072 002 Jul 22, 2009 Jul NEWA
>A>		10MG	N78072 004 Jul 22, 2009 Jul NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AVANTHI INC 12MG

N40829 001 May 13, 2009 Apr NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
 DELSYM
 + RECKITT BENCKISER EQ 30MG HBR/5ML N18658 001 Oct 08, 1982 Feb CAHN

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE
 DR REDDYS LABS LTD 38MG;200MG N90619 001 Jul 08, 2009 Jun NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION
 PRIMATENE MIST
 @ WYETH CONS 0.2MG/INH N16126 001 Jun DISC

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION
 BRONITIN MIST
 @ WYETH CONS 0.3MG/INH N16126 002 Jun DISC

IBUPROFEN

CAPSULE; ORAL
 IBUPROFEN
 BANNER PHARMACAPS EQ 200MG FREE ACID AND POTASSIUM SALT N78682 001 Mar 24, 2009 Mar NEWA

>A> DR REDDYS LABS LTD EQ 200MG FREE ACID AND POTASSIUM SALT N77338 001 Jul 10, 2009 Jul NEWA

>A> EQ 200MG FREE ACID AND POTASSIUM SALT N77338 001 Jul 10, 2009 Jul NEWA

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT N77338 001 Jul 10, 2009 Jun NEWA
 EQ 200MG FREE ACID AND POTASSIUM SALT N79205 001 Jun 26, 2009 Jun NEWA

MIDLOL LIQUID GELS
 + BANNER PHARMACAPS 200MG N21472 001 Oct 18, 2002 Feb CTNA

TABLET; ORAL
 IBUPROFEN
 @ SANDOZ 200MG N70733 001 Sep 19, 1986 Mar DISC
 MEDIPREN
 @ MCNEIL 200MG N70475 001 Feb 06, 1986 Apr DISC
 @ 200MG N71215 001 Jun 26, 1986 Apr DISC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
 HUMULIN 50/50
 @ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 Apr 29, 1992 Jan DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
 PREVACID 24 HR
 + NOVARTIS 15MG N22327 001 May 18, 2009 May NEWA

LEVONORGESTREL

TABLET; ORAL
 PLAN B ONE-STEP
 >A> + DURAMED 1.5MG N21998 001 Jul 10, 2009 Jul NEWA

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL							
PROSTEP							
@ AVEVA	11MG/24HR						N19983 003 Dec 23, 1998 Jun DISC
@	22MG/24HR						N19983 004 Dec 23, 1998 Jun DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL							
NICOTINE POLACRILEX							
IVAX PHARMS	EQ 2MG BASE						N76880 001 Feb 18, 2009 Feb NEWA
	EQ 4MG BASE						N77850 001 Feb 18, 2009 Feb NEWA
WATSON LABS	EQ 2MG BASE						N79044 001 Jul 08, 2009 Jun NEWA
	EQ 2MG BASE						N79216 001 Jul 08, 2009 Jun NEWA
	EQ 4MG BASE						N79038 001 Jul 08, 2009 Jun NEWA
	EQ 4MG BASE						N79219 001 Jul 08, 2009 Jun NEWA
TROCHE/LOZENGE; ORAL							
NICORETTE							
GLAXOSMITHKLINE CONS	EQ 2MG BASE						N22360 001 May 18, 2009 May NEWA
+	EQ 4MG BASE						N22360 002 May 18, 2009 May NEWA
NICOTINE POLACRILEX							
PERRIGO R AND D	EQ 2MG BASE						N90711 001 Jul 10, 2009 Jun NEWA
	EQ 2MG BASE						N90821 001 Jul 10, 2009 Jun NEWA
	EQ 4MG BASE						N90711 002 Jul 10, 2009 Jun NEWA
	EQ 4MG BASE						N90821 002 Jul 10, 2009 Jun NEWA

POTASSIUM IODIDE

SOLUTION; ORAL							
>D>	POTASSIUM IODIDE						
>D>	@ ROXANE	1GM/ML					N18551 001 Feb 19, 1982 Jul DISC
>A>	@	1GM/ML					N18551 001 Feb 19, 1982 Jul DISC
	THYROSHIELD						
+	FLEMING	65MG/ML					N77218 001 Jan 12, 2005 Apr CRLD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL							
RANITIDINE							
>D>	RANBAXY	EQ 75MG BASE					N75132 001 Jan 14, 2000 Jul DISC
>A>	@	EQ 75MG BASE					N75132 001 Jan 14, 2000 Jul DISC
	@ SANDOZ	EQ 75MG BASE					N75519 001 Sep 26, 2002 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2009

NO JULY 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
022320 001	4717720	May 31, 2010	DS DP			
	RE34440	May 31, 2010		U-818		
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALISKIREN FUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
022107 001				>A> I-600		Jul 16, 2012
<u>ALISKIREN FUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
022107 002				>A> I-600		Jul 16, 2012
<u>ALISKIREN FUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
022107 003				>A> I-600		Jul 16, 2012
<u>ALISKIREN FUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
022107 004				>A> I-600		Jul 16, 2012
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 001	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 002	5565447	May 07, 2015	DS DP U-969			
	5565447*PED	Nov 07, 2015				
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 001				PC		Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 002				PC		Jul 13, 2009

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
	078088 003				PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
	078088 004				PC	Jul 13, 2009
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 005	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 006	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 007	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 008	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 009	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 010	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 011	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 001	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 002	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 003	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 004	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 005	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
022119 001					NCE W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010		U-452		
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>ANASTROZOLE - ARIMIDEX</u>						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 001	5965525	Feb 17, 2020	DS DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 002	5965525	Feb 17, 2020	DS DP U-540			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
021866 001	>A> 7550445	Jul 21, 2024	DP			
	>A> 7550445*PED	Jan 21, 2025				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 001	4927855	Apr 22, 2010	DS DP U-820			
	4927855*PED	Oct 22, 2010				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 002	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 003	4927855	Apr 22, 2010	DS DP U-820			
	4927855*PED	Oct 22, 2010				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 004	4927855	Apr 22, 2010	DS DP U-820			
	4927855*PED	Oct 22, 2010				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 005	4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	4927855*PED	Oct 22, 2010				
	7132570	Dec 18, 2023	DS DP			
	7132570*PED	Jun 18, 2024				
	7297346	Nov 29, 2023	DP			
	7297346*PED	May 29, 2024				
	RE37516	Oct 06, 2014	DP U-820			
	RE37516*PED	Apr 06, 2015				
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
021248 001	6982096	Nov 10, 2018	U-651			
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
022268 001	5677331	Oct 14, 2014	DP U-977		NCE	Apr 07, 2014
					ODE	Apr 07, 2016
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE</u>						
021078 001	>A> 5998449	Nov 25, 2013		U-990		
	>A> 5998449*PED	May 25, 2014				
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - MALARONE PEDIATRIC</u>						
021078 002	>A> 5998449	Nov 25, 2013		U-990		
	>A> 5998449*PED	May 25, 2014				
<u>AZITHROMYCIN - AZASITE</u>						
050810 001	5192535	Mar 09, 2010	DP	U-709		
	>A> 6159458	Nov 04, 2017	DP	U-709		
	6239113	Mar 31, 2019		U-709		
	6569443	Mar 31, 2019	DP	U-709		
	6861411	Nov 25, 2018		U-709		
	7056893	Mar 31, 2019	DP	U-709		
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
022249 002					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
050819 001	5733886	Mar 31, 2015	DP	U-124		
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
050741 001	5466446	Feb 16, 2014	DS	DP		
<u>BENZYL ALCOHOL - ULESFIA</u>						
022129 001	5858383	Aug 11, 2017		U-970		
	6139859	Aug 11, 2017		U-970		
	6793931	Jul 11, 2022	DP	U-970		
	7294342	May 19, 2024		U-970		
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
022308 001	5447926	Sep 05, 2012	DS	DP	U-80	
	6685958	Jun 29, 2021	DP		U-80	
	6699492	Mar 31, 2019	DP		U-80	
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	May 24, 2017	DP			
<u>BIMATOPROST - LATISSE</u>						
022369 001					NP	Dec 24, 2011
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
050786 001	5196205	Mar 23, 2010		U-933		
	5476669	Mar 23, 2010		U-933		
	6350468	Dec 14, 2018		U-956		
	6350468	Dec 14, 2018		U-932		
<u>BIVALIRUDIN - ANGIOMAX</u>						
020873 001	5196404	Mar 23, 2010				
	5196404*PED	Sep 23, 2010				
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
021398 001	>A> 7323463	Jan 19, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
020866 001	5468755	Nov 21, 2012	U-976		NP	May 05, 2012
	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015	U-976			
	5756513	Nov 21, 2012	U-976			
	5866584	Nov 21, 2012	U-976			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 001	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 002	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 003	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 001				I-582	Feb 27, 2012	
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 002				I-582	Feb 27, 2012	
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
021406 001	RE40812	Feb 02, 2021	DP			
<u>CALCITRIOL - VECTICAL</u>						
022087 001				NDF	Jan 23, 2012	
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018	U-353			
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018	U-353			
	6015801*PED	Jan 17, 2019				
	6096342	Nov 21, 2011	DP			
	6096342*PED	May 21, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018	U-595			
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 001	>A> 5196444	Jun 04, 2012	DS DP U-660			
	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-660			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 002	>A> 5196444	Jun 04, 2012	DS DP U-660			
	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-660			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 003	>A> 5196444	Jun 04, 2012	DS DP U-660			
	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-660			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 004	>A> 5196444	Jun 04, 2012	DS DP U-660			
	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-660			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 001	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-3			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 002	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-3			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 003	>A> 5196444	Jun 04, 2012	DS DP U-3			
	>A> 5196444*PED	Dec 04, 2012				
	>A> 5534534	Jul 09, 2013	DP			
	>A> 5534534*PED	Jan 09, 2014				
	>A> 5705517	Apr 18, 2011	DS DP U-3			
	>A> 5705517*PED	Oct 18, 2011				
	>A> 7538133	Apr 18, 2011	DS			
	>A> 7538133*PED	Oct 18, 2011				
<u>CICLESONIDE - ALVESCO</u>						
021658 002				NDF	Jan 10, 2011	
				NCE	Oct 20, 2011	
<u>CICLESONIDE - ALVESCO</u>						
021658 003				NDF	Jan 10, 2011	
				NCE	Oct 20, 2011	
<u>CICLESONIDE - OMNARIS</u>						
022004 001	>A> 5482934	Oct 24, 2017	DS DP U-557			
<u>CIPROFLOXACIN HYDROCHLORIDE - CETRAXAL</u>						
021918 001				NDF	May 01, 2012	
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
020805 001	5843930	Jun 06, 2015	U-646			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
050775 001	6551616	Jul 15, 2017	U-924			
<u>CLOBETASOL PROPIONATE - OLUX</u>						
021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>COLCHICINE - COLCRYS</u>						
022352 001				>A> I-603	Jul 30, 2012	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021176 001	5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
	5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS	U-323		
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS	U-323		
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP	U-757		
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022		U-851		
	7229613*PED	Oct 17, 2022				
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
021777 001	7544372	Nov 14, 2023	U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
021777 002	7544372	Nov 14, 2023	U-979			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 001	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 002	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 003	7511014	Feb 16, 2010	DP			
<u>DASATINIB - SPRYCEL</u>						
021986 001	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
021986 002	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 003	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 004	6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
	7491725	Oct 13, 2025	DS DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
022201 001	5925730	Apr 11, 2017	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
022201 002	5925730	Apr 11, 2017	DS DP U-943			
<u>DESONIDE - DESONATE</u>						
021844 001					NDF	Oct 20, 2009
<u>DEXAMETHASONE - OZURDEX</u>						
022315 001	6726918	Oct 20, 2020	DP U-985		NDF	Jun 17, 2012
	6899717	Nov 01, 2023	U-985			
	7033605	Oct 20, 2020	DP			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
050818 001	5149694	Sep 22, 2009	U-953			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
022165 001	>A> 6974595	May 15, 2017	U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
022202 001	6365180	Jul 16, 2019	DP U-980		NDF	Jun 16, 2012
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP U-107			
	5470584	May 20, 2011	DP			
<u>DINOPROSTONE - CERVIDIL</u>						
020411 001	5269321	Jul 14, 2012	DP U-110			
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
077567 002					PC	Aug 01, 2009
<u>DOXERCALCIFEROL - HECTOROL</u>						
020862 001	>A> 5602116	Feb 11, 2014	U-987			
	>A> 5602116	Feb 11, 2014	U-278			
	>A> 6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
020862 002	>A> 5602116	Feb 11, 2014	U-987			
	>A> 5602116	Feb 11, 2014	U-278			
	>A> 6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
020862 003	>A> 5602116	Feb 11, 2014	U-987			
<u>DOXERCALCIFEROL - HECTOROL</u>						
021027 001	5707980	Aug 17, 2010	U-321	Y		
	>A> 6903083	Jul 18, 2021	DS DP		Y	
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
022425 001	>A> 5223510	Jul 26, 2011	DS DP U-992		>A> NCE	Jul 01, 2014
	>A> 7323493	Jun 19, 2018	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
	7547719	Mar 04, 2024	DS DP U-930			
<u>EPINEPHRINE - EPIPEN</u>						
019430 001	7449012	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
019430 002	7449012	Sep 11, 2025	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 001					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 002					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 003					NPP	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021365 001					NPP	Mar 19, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 001					NPP	Apr 28, 2009
					PED	Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 002					NPP	Apr 28, 2009
					PED	Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 001					M-86	Jun 18, 2012
					NPP	Apr 28, 2009
					PED	Dec 18, 2012
					PED	Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 002					M-86	Jun 18, 2012
					NPP	Apr 28, 2009
					PED	Dec 18, 2012
					PED	Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
022101 001					NPP	Feb 27, 2011
					PED	Aug 27, 2011
<u>ESTRADIOL - ELESTRIN</u>						
021813 001	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
022014 001	6818226	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6978945	Nov 30, 2021	DP			
<u>ETHINYL ESTRADIOL; NORGESTIMATE - TRI LO SPRINTEC</u>						
076784 001					>A> PC	Dec 29, 2009
<u>EVEROLIMUS - AFINITOR</u>						
022334 001	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 001	7521423	Oct 15, 2017	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 002	7521423	Oct 15, 2017	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
022266 001				>A> NP		Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
022266 002				>A> NP		Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
022266 003				>A> NP		Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
022266 004				>A> NP		Jul 16, 2012
<u>FENTANYL CITRATE - ONSOLIS</u>						
022266 005				>A> NP		Jul 16, 2012
<u>FERUMOXYTOL - FERAHEME</u>						
022180 001	>A> 6599498	Mar 08, 2020	DS DP		NP	Jun 30, 2012
	>A> 7553479	Mar 08, 2020	DS DP			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 001	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 002	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 003	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 004	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 005	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUTICASONE FUBROATE - VERAMYST</u>						
022051 001	>A> 7541350	Aug 03, 2021	DP U-988			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015		U-710		
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015		U-582		
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018		DP		
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015		U-583		
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-581		
	6743413*PED	Dec 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 001	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015		U-738		
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015		U-738		
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018	DP			
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015	DP			
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018	DP			
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019	DP			
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018	DP			
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015	DP			
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018	DP			
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019	DP			
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025	DP			
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 001				M-83		Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 002				M-83		Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 003				M-83		Apr 14, 2011
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
020378 004	>A> 7563763	Aug 23, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
020378 005	>A> 7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
021684 001	>A> 7446090	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
021684 002	>A> 7446090	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF PEN</u>						
021684 003	>A> 7446090	Aug 23, 2019	DP			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013
<u>GADODIAMIDE - OMNISCAN</u>						
022066 002	5362475	Nov 08, 2011	DS			
<u>GATIFLOXACIN - ZYMAR</u>						
021493 001	4980470	Dec 15, 2009	DS DP			
	4980470*PED	Jun 15, 2010				
	5880283	Dec 05, 2015				
	5880283*PED	Jun 05, 2016				
	6333045	Aug 20, 2019	DP			
	6333045*PED	Feb 20, 2020				
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 001				I-594	Feb 27, 2012	
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 002				I-594	Feb 27, 2012	
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 001	7538125	Jun 19, 2016	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 002	7538125	Jun 19, 2016	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
019726 001	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
020578 001	7500964	Feb 26, 2021	DP			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>IBUPROFEN - CALDOLOR</u>						
022348 001	6727286	Nov 27, 2021	DP U-981		NP	Jun 11, 2012
<u>IBUPROFEN - CALDOLOR</u>						
022348 002	6727286	Nov 27, 2021	DP U-981		NP	Jun 11, 2012
<u>ILOPERIDONE - FANAPT</u>						
022192 001	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 002	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
022192 003	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 004	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 005	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 006	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 007	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001					I-583	Dec 19, 2011
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002					I-583	Dec 19, 2011
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001	5750497	May 16, 2019	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
021629 002					NCE	Apr 16, 2009
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
021629 003					NPP NCE	Oct 24, 2011 Apr 16, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020351 002	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020808 002	RE36418	Jul 12, 2011	DP			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 001	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEM普RA KIT</u>						
022065 002	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
<u>KETOCONAZOLE - EXTINA</u>						
021738 001	>A> 7553835	Oct 19, 2018	DP U-245			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
022427 001				>A> NP		Jul 22, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001				M-85	Oct 28, 2011	
				PED	Apr 28, 2012	
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002				M-85	Oct 28, 2011	
				PED	Apr 28, 2012	
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001				M-85	Oct 28, 2011	
				PED	Apr 28, 2012	
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002				M-85	Oct 28, 2011	
				PED	Apr 28, 2012	
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	7431942	May 17, 2019	DP		M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	7431942	May 17, 2019	DP		M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			PED	Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID 24 HR</u>						
022327 001					NP	May 18, 2012
<u>LANSOPRAZOLE - PREVACID IV</u>						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 001	5968976	Oct 26, 2018	DP U-613			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 002	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Oct 26, 2018	DP U-613			
<u>LEVETIRACETAM - KEPPRA XR</u>						
022285 002				NDF		Sep 12, 2011
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
021998 001				>A> NP		Jul 10, 2012
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
022114 001				NPP		Jan 08, 2012
<u>MALATHION - OVIDE</u>						
018613 001	7560445	Feb 01, 2027	DS DP U-986			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 001	5061703	Apr 11, 2015		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 002	5061703	Apr 11, 2015		U-539		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021627 001	5061703	Apr 11, 2015		U-539		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
022024 001	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
022024 002	4687777	Jan 17, 2011	DS			
	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
050808 002	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
050808 004	>A> 5908838	Feb 19, 2018	U-917			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
050808 005	>A> 5908838	Feb 19, 2018	U-917			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
021260 006	6066339	Nov 25, 2017	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
022360 001	5110605	Aug 21, 2010	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
022360 002	5110605	Aug 21, 2010	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
021780 001	5869082	Apr 16, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
020592 001	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 002	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 003	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 004	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 005	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 006	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 001	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 002	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 003	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 004	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
021545 001	>A> 5116863	Dec 18, 2010	DS DP			
	>A> 5116863*PED	Jun 18, 2011				
	>A> 5641805	Jun 06, 2015	U-765			
	>A> 5641805*PED	Dec 06, 2015				
	>A> 6995186	Nov 12, 2023	DP U-765			
	>A> 6995186*PED	May 12, 2024				
	>A> 7402609	Jun 19, 2022	DP			
	>A> 7402609*PED	Dec 19, 2022				
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
021861 001	>A> 5116863	Dec 18, 2010	DS DP		>A> NDF	Apr 15, 2011
	>A> 5116863*PED	Jun 18, 2011			>A> PED	Oct 15, 2011
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
020688 001	>A> 5116863	Dec 18, 2010				
	>A> 5116863*PED	Jun 18, 2011				
	>A> 5641805	Jun 06, 2015	U-184			
	>A> 5641805*PED	Dec 06, 2015				
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
021654 001	5656667	Apr 10, 2017	DS DP U-822			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
022204 001	7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	7179483	Apr 26, 2020	U-318			
<u>PALIPERIDONE - INVEGA</u>						
021999 006	5158952	Oct 27, 2009	DP U-90			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 002	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				
	7544370	Feb 07, 2026	DP			
	7544370*PED	Aug 07, 2026				
	>A> 7550153	Sep 30, 2024	U-859			
	>A> 7550153*PED	Mar 30, 2025				
	>A> 7553498	Sep 30, 2024	U-859			
	>A> 7553498*PED	Mar 30, 2025				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				
<u>PARICALCITOL - ZEMPLAR</u>						
021606 001				I-599	Jun 29, 2012	
<u>PARICALCITOL - ZEMPLAR</u>						
021606 002				I-599	Jun 29, 2012	
<u>PARICALCITOL - ZEMPLAR</u>						
021606 003				I-599	Jun 29, 2012	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
021462 001				>A> I-601	Jul 02, 2012	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
021462 002				>A> I-601	Jul 02, 2012	
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
022159 001	6764678	May 11, 2021	U-967			
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 002	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 003	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
022307 001	>A> 5288726	Sep 08, 2012	DS DP U-991	>A> NCE		Jul 10, 2014
	>A> 6693115	Jul 03, 2021	DS DP U-991			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
022307 002	>A> 5288726	Sep 08, 2012	DS DP U-991	>A> NCE		Jul 10, 2014
	>A> 6693115	Jul 03, 2021	DS DP U-991			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001	4879288	Sep 26, 2011	DS DP U-550	I-560	May 13, 2011	
	4879288*PED	Mar 26, 2012		I-503	Oct 20, 2009	
				PED	Nov 13, 2011	
				PED	Apr 20, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002	4879288	Sep 26, 2011	DS DP U-550	I-560	May 13, 2011	
	4879288*PED	Mar 26, 2012		I-503	Oct 20, 2009	
				PED	Nov 13, 2011	
				PED	Apr 20, 2010	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003	4879288	Sep 26, 2011	DS DP U-550	I-560	May 13, 2011	
	4879288*PED	Mar 26, 2012		I-503	Oct 20, 2009	
				PED	Nov 13, 2011	
				PED	Apr 20, 2010	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 001	5453446	Feb 07, 2017		U-219		
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 002	5453446	Feb 07, 2017		U-219		
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REPAGLINIDE - PRANDIN</u>						
020741 001	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 002	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 003	6677358	Jun 12, 2018	DS DP U-968			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 001	5583122	Dec 10, 2013	U-222		>A> M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			>A> PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 002	5583122	Dec 10, 2013	U-222		>A> M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			>A> PED	Jan 23, 2013
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 003	5583122	Dec 10, 2013	DS DP U-756		I-309	Aug 11, 2009
	5583122	Dec 10, 2013	DS DP U-222	>A>	M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014		>A>	PED	Jan 23, 2013
	5994329	Jul 17, 2018	U-353		PED	Feb 11, 2010
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018	U-353			
	6015801*PED	Jan 17, 2019				
	6096342	Nov 22, 2011	DP			
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018	U-595			
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 004	5583122	Dec 10, 2013	DS DP U-353		D-105	Apr 16, 2010
	5583122*PED	Jun 10, 2014		>A>	M-61	Jul 23, 2012
	6096342	Nov 22, 2011	DP U-353	>A>	PED	Jan 23, 2013
	6096342*PED	May 22, 2012			PED	Oct 16, 2010
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 005	5583122	Dec 10, 2013	DS DP U-353		>A> M-61	Jul 23, 2012
	5583122*PED	Jun 10, 2014			NS	Apr 22, 2011
	6165513	Jun 10, 2018	DP	>A>	PED	Jan 23, 2013
	6165513*PED	Dec 10, 2018			PED	Oct 22, 2011
	7192938	May 06, 2023	U-353			
	7192938*PED	Nov 06, 2023				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 001	5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 002	5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 003	5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 004	5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	7547452	Nov 19, 2013	DP			
	7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERIDONE</u>						
076440 001					PC	Jul 29, 2009
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
022008 006	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 002	6316460	Aug 04, 2020	DP		I-573	Nov 06, 2011
	6316460*PED	Feb 04, 2021			I-547	Nov 08, 2010
	6858618	Dec 17, 2021	U-618		PED	May 06, 2012
	6858618*PED	Jun 17, 2022			PED	May 08, 2011
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 003	6316460	Aug 04, 2020	DP		I-573	Nov 06, 2011
	6316460*PED	Feb 04, 2021			I-547	Nov 08, 2010
	6858618	Dec 17, 2021	U-618		PED	May 06, 2012
	6858618*PED	Jun 17, 2022			PED	May 08, 2011
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 004	6316460	Aug 04, 2020	DP		I-573	Nov 06, 2011
	6316460*PED	Feb 04, 2021			I-547	Nov 08, 2010
	6858618	Dec 17, 2021	U-618		PED	May 06, 2012
	6858618*PED	Jun 17, 2022			PED	May 08, 2011
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 005	6316460	Aug 04, 2020	DP		I-573	Nov 06, 2011
	6316460*PED	Feb 04, 2021			I-547	Nov 08, 2010
	6858618	Dec 17, 2021	U-618		PED	May 06, 2012
	6858618*PED	Jun 17, 2022			PED	May 08, 2011
	RE37314	Jan 08, 2016	DS			
	RE37314*PED	Jul 08, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
022181 001	>A> 7566462	Nov 16, 2025	DP			
	>A> 7566714	Nov 17, 2024	U-989			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
022350 001				>A> NCE		Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
022350 002				>A> NCE		Jul 31, 2014
<u>SILDENAFIL CITRATE - REVATIO</u>						
021845 001				I-598		May 07, 2009
<u>SILODOSIN - RAPAFLO</u>						
022206 001	5780485	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
022206 002	5780485	Nov 13, 2012	U-902			
<u>SINECATECHINS - VEREGEN</u>						
021902 001	5795911	Oct 31, 2020	U-172			
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 001				I-585		Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 004	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 005	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 006	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 007	5849700	Dec 15, 2015	U-340	I-572	Oct 31, 2011	
	5849704	Dec 15, 2015	DP U-340	I-551	Sep 20, 2010	
				I-536	May 31, 2010	
				ODE	May 31, 2014	
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
019764 002	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
019764 003	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
020604 001	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
020604 002	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
020604 003	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
020604 004	>A> 5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
021597 004	>A> 5288703	Oct 07, 2011	U-898			
	>A> 5898030	Apr 27, 2016	DP			
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076572 001				PC	Aug 08, 2009	
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 001				PC	Aug 08, 2009	
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 002				PC	Aug 08, 2009	
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 003				PC	Aug 08, 2009	
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
022239 001	>A> 5891086	Jul 27, 2014	DP			
	>A> 5957886	Mar 08, 2016	DP			
	>A> 6135979	Mar 21, 2017	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
021938 004	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011	
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - ADCIRCA</u>						
022332 001	5859006	Nov 21, 2017	DS DP U-975		NP ODE	May 22, 2012 May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TELBIVUDINE - TYZEKA</u>						
022154 001					NCE	Oct 25, 2011
<u>TEMOZOLOMIDE - TEMODAR</u>						
022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
021318 001	7550434	Dec 08, 2018	DP U-982		>A> I-602	Jul 22, 2012
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
021318 002	6770623	Dec 08, 2018	DP U-982		>A> I-602	Jul 22, 2012
	6977077	Aug 19, 2019	U-982			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7351414	Aug 19, 2019	U-984			
	7550434	Dec 08, 2018	DP U-982			
<u>TIGECYCLINE - TYGACIL</u>						
021821 001					I-588 I-587 I-586	Mar 20, 2012 Mar 20, 2012 Mar 20, 2012
<u>TOLVAPTAN - SAMSCA</u>						
022275 001	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOLVAPTAN - SAMSCA</u>						
022275 002	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOLVAPTAN - SAMSCA</u>						
022275 003	5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	5753677	May 19, 2015		U-978		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 001	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	7498311	Oct 13, 2015		U-955		
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 001				PC		Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 002				PC		Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 001				PC		Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 002				PC		Oct 12, 2009
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 001				NP		Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 002				NP		Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 003				NP		Dec 30, 2011
<u>TREPROSTINIL SODIUM - TYVASO</u>						
022387 001				>A> NDF		Jul 30, 2012
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
022278 001				NCE		Dec 16, 2009
				ODE		Dec 16, 2011
<u>ZOLEDRONIC ACID - RECLAST</u>						
021817 001				I-595		May 29, 2012
				I-584		Mar 15, 2012
				I-581		Dec 19, 2011
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 001	6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 002	6761910	Sep 24, 2018	DP U-674			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>